

1 **The influence of biological, epidemiological, and treatment**  
2 **factors on the establishment and spread of drug-resistant**  
3 ***Plasmodium falciparum***

4 Thierry Masserey<sup>1, 2</sup>, Tamsin Lee<sup>1, 2</sup>, Monica Golumbeanu<sup>1, 2</sup>, Andrew J Shattock<sup>1, 2</sup>, Sherrie L Kelly<sup>1, 2</sup>,  
5 Ian M Hastings<sup>3</sup>, Melissa A Penny<sup>1, 2\*</sup>

6 <sup>1</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

7 <sup>2</sup> University of Basel, Basel, Switzerland

8 <sup>3</sup> Liverpool School of Tropical Medicine, Liverpool, UK

9 \*corresponding author: melissa.penny@unibas.ch

10 **Abstract**

11 The effectiveness of artemisinin-based combination therapies (ACTs) to treat *Plasmodium*  
12 *falciparum* malaria is threatened by resistance. The complex interplay between sources of  
13 selective pressure – treatment properties, biological factors, transmission intensity, and access  
14 to treatment – obscures understanding how, when, and why resistance establishes and  
15 spreads across different locations. We developed a disease modelling approach with emulator-  
16 based global sensitivity analysis to systematically quantify which of these factors drive  
17 establishment and spread of drug resistance. Drug resistance was more likely to evolve in low  
18 transmission settings due to the lower levels of (i) immunity and (ii) within-host competition  
19 between genotypes. Spread of parasites resistant to artemisinin partner drugs depended on  
20 the period of low drug concentration (known as the selection window). Spread of partial  
21 artemisinin resistance was slowed with prolonged parasite exposure to artemisinin derivatives  
22 and accelerated when the parasite was also resistant to the partner drug. Thus, to slow the  
23 spread of partial artemisinin resistance, molecular surveillance should be supported to detect  
24 resistance to partner drugs and to change ACTs accordingly. Furthermore, implementing more  
25 sustainable artemisinin-based therapies will require extending parasite exposure to artemisinin  
26 derivatives, and mitigating the selection windows of partner drugs, which could be achieved by  
27 including an additional long-acting drug.

28 **Impact Statement:**

29 Detailed models of malaria and treatment dynamics were combined with emulator-based  
30 global sensitivity analysis to elucidate how the interplay of drug properties, infection biology,  
31 and epidemiological dynamics drives evolution of resistance to artemisinin-based combination  
32 therapies. The results identify mitigation strategies.

## 33 Introduction:

34 Malaria remains a global health priority [1]. The World Health Organization (WHO)  
35 recommends several artemisinin-based combination therapies (ACTs) to treat uncomplicated  
36 *Plasmodium falciparum* malaria [2]. ACTs combine a short-acting artemisinin derivative to  
37 rapidly reduce parasitaemia during the first three days of treatment and a long-acting partner  
38 drug to eliminate remaining parasites [2]. These drug combinations are intended to delay the  
39 evolution of drug resistance, which has frequently occurred under monotherapy treatment [3-  
40 6]. However, parasites partially resistant to artemisinin have emerged in the Greater Mekong  
41 Subregion (GMS) and, more recently, in Rwanda, Uganda, Guyana, and Papua New Guinea  
42 despite the use of ACTs [2, 7-11]. Partial artemisinin resistance leads to slower parasite  
43 clearance following treatment with ACTs, but not necessarily to treatment failure [2]. However,  
44 high rates of treatment failure have been observed in the GMS due to parasites being less  
45 sensitive to artemisinin derivatives and their partner drugs [2]. To prevent the evolution of drug-  
46 resistant parasites and to preserve the efficacy of ACTs or triple combination therapies (TACT,  
47 including a second long-acting drug) now being tested [12], it is essential to understand which  
48 factors drive this process.

49 The evolution of drug resistance follows a three-step process of mutation, establishment, and  
50 spread. First, mutations conferring drug resistance emerge in the population at a rate that  
51 depends on multiple factors, such as organism mutation and migration rates [13, 14]. Second,  
52 establishment is a highly stochastic step as the parasite with the drug-resistant mutation needs  
53 to infect other hosts [13-16]. The resistant strain establishes in the population once its  
54 frequency is high enough to minimise its risk of stochastic extinction [13-16]. Several forces  
55 influence the establishment of mutations. In settings with higher heterogeneity of parasite  
56 reproductive success, establishment of mutations is less likely because the effects of  
57 stochasticity are more substantial [13, 15-17]. This heterogeneity depends on the level of  
58 transmission and health system strength [13, 15-18]. In addition, the more selection favours  
59 the resistant strain, the more likely it is to establish [13, 15-17]. The strength of selection  
60 depends on many factors, such as the parasite and human biology, the transmission setting,  
61 drug properties, and health system strength [5, 19-24]. Third, resistance spreads through a  
62 region after a resistant mutation has become established. The mutation spreads at a rate that  
63 depends on the strength of selection [13, 16].

64 It is not fully understood how factors intrinsic to the transmission setting, health system, human  
65 and parasite biology, and drug properties interact to influence the establishment and spread  
66 of drug-resistant parasites. Mathematical models of infectious disease have not previously  
67 been used to systematically assess the joint influence of multiple factors on the establishment  
68 and spread of drug resistance, e.g. [23, 25-37]. Simple models, based on the Ross and  
69 MacDonald model [38, 39], have considered specific components of the epidemiology of  
70 resistance and, therefore, are not sophisticated enough to answer questions on how factors  
71 have jointly impacted establishment and spread of drug resistance [26, 30-33, 36, 37]. Most  
72 models have investigated specific transmission scenarios and questions, such as how within-  
73 host competition between parasites influences development of drug resistance [25, 28, 35],  
74 and did not systematically assess the impact of assumptions used on their results.  
75 Consequently, previous studies have not systematically compared the influence of multiple  
76 drivers, nor assessed how their influence varies under different transmission settings or health  
77 system strengths.

78 In addition, most models have made simplifications concerning drug action and consequences  
79 of partial resistance. They have not explicitly modelled the pharmacokinetics and  
80 pharmacodynamics of the drugs and have assumed that resistant parasites are fully resistant  
81 to the drugs. Parasites partially resistant to artemisinin exhibit an extended ring-stage during  
82 which they are not sensitive to artemisinin, however, parasites remain sensitive to artemisinin  
83 during other stages [40-44]. In addition, parasites resistant to partner drugs have an increased  
84 minimum inhibitory concentration (MIC), meaning that they are not sensitive to low drug  
85 concentrations but remain susceptible to high concentrations of partner drugs [45-47].  
86 Consequently, many models have ignored the residual effect of drugs on resistant parasites  
87 and have not investigated the influence of the degree of resistance and drug properties on the  
88 establishment and spread of drug resistance. Models that have explicitly considered drug  
89 action have focused on specific questions such as how half-life impacts the spread of  
90 resistance or how resistance to the partner drug influences evolution of artemisinin resistance  
91 [48, 49]. However, they did not investigate how the impact of drug properties and the degree  
92 of resistance interact with other biological, transmission, and health system factors.

93 In this study, we developed a disease model with an emulator-based approach to quantify the  
94 influence of factors intrinsic to the biology of the parasite and human, the transmission setting,  
95 the health system strength, and the drug properties on the establishment and spread of drug-  
96 resistant parasites. Our approach is based on a detailed individual-based malaria model,  
97 OpenMalaria (<https://github.com/SwissTPH/openmalaria/wiki>), that includes a mechanistic  
98 within-host model (based on [50]). We first adapted our model, OpenMalaria, to explicitly  
99 include mechanistic drug action models at the individual level (as a one, two, or three-  
100 compartment pharmacokinetic model with a pharmacodynamics component of parasite killing  
101 [51-54]) and to track multiple parasite genotypes to which we could assign fitness costs and  
102 drug susceptibility (i.e. pharmacodynamic) properties. We then built an emulator-based  
103 workflow to quantify, through a series of global sensitivity analyses, the influence of multiple  
104 factors on the establishment and spread of parasites having different degrees of resistance to  
105 artemisinin derivatives and/or their partner drugs when used in monotherapy and combination  
106 (as ACTs). Emulators are predictive models that can approximate the relationship between  
107 input and output parameters of complex models and can run much faster than complex models  
108 to perform global sensitivity analyses more efficiently [55]. OpenMalaria is a mechanistic  
109 model, so the observed dynamics at the population level (for example, the spread of resistant  
110 genotypes) emerges from the relationship between the different model components and their  
111 input parameters. These dynamics can only be understood and tested through extensive  
112 analyses as undertaken here. Identifying which factors (e.g. drug properties and/or setting  
113 characteristics) favour the evolution of resistance, enables us to identify drug properties or  
114 strategies to slow or mitigate resistance and guides the development and implementation of  
115 more sustainable therapies.

## 116 **Results**

### 117 **Development of drug resistance**


118 We investigated the establishment and spread of drug-resistant genotypes by varying the  
119 degrees of resistance for three different treatment profiles. The first treatment profile  
120 considered was a monotherapy using a short-acting drug referred to in this study as drug A.  
121 Drug A has a short half-life and a high killing efficacy, simulating artemisinin derivatives (Figure  
122 1A and 1B). Patients received a daily dose of drug A for six days (see Methods). To mimic the  
123 mechanism of resistance to artemisinin derivatives, we assumed that genotypes resistant to  
124 drug A had lower maximum killing rates ( $E_{max}$ ) than sensitive ones (Figure 1B) (see Methods).  
125 We defined the degree of resistance to drug A as the relative decrease of the  $E_{max}$  of the  
126 resistant genotype compared with the sensitive one. The second treatment profile was also a  
127 monotherapy but with a long-acting drug referred to in this study as drug B. Drug B has a  
128 longer half-life and a lower  $E_{max}$  than drug A, typical of partner drugs used for ACTs (such as  
129 mefloquine, piperaquine, and lumefantrine) (Figure 1A and 1B). Patients received a daily dose  
130 of drug B for three days (see Methods). We assumed that genotypes resistant to drug B had  
131 higher half-maximal effective concentrations ( $EC_{50}$ ) than sensitive ones (Figure 1B) (see  
132 Methods). We defined the degree of resistance to drug B as the relative increase of the  $EC_{50}$   
133 of the resistant genotype compared with the sensitive genotype. The last treatment profile was  
134 a daily dose of a combination of drugs A and B for three days, simulating ACTs. In this last  
135 case, only the resistant genotype had some degree of resistance to drug A, but both the  
136 sensitive and resistant genotypes could have the same degree of resistance to drug B.

137 Our analysis had two steps. First, we quantified the impact of factors listed in Table 1 on the  
138 spread of drug-resistant parasites through global sensitivity analyses using an emulator trained  
139 on our model simulations (Figure 1C, purple area, see Methods). For each simulation, we  
140 tracked a drug-sensitive genotype and a drug-resistant genotype, and we estimated the rate  
141 of spread using the selection coefficient, which measures the rate at which the logit of the  
142 resistant genotype frequency increases each parasite generation (see Methods, note that a  
143 selection coefficient below zero implies that resistance does not spread in the population) [16].  
144 Then, we assessed the probability of establishment for a sub-set of resistant genotypes with  
145 known and positive selection coefficients to observe the relationship between selection  
146 coefficient and the probability of establishment (Figure 1C, orange area, see Methods). We  
147 could then extrapolate the probability of establishing any mutations with a known selection  
148 coefficient, which made the process more efficient since estimating the probability of  
149 establishment requires running many more stochastic realisations than estimating the  
150 selection coefficient due to the stochasticity of this step.

151 **Figure 1**

152 **Overview of treatment profiles and the workflow.**

153 (A) Curves represent examples of the modelled within-host concentration (mg/l) of drugs A (short-acting  
154 like artemisinin derivatives) and B (long-acting like partner drugs of artemisinin) used in monotherapy.  
155 Patients received a daily dose of drug A for six days (see Methods). Patients received a daily dose of  
156 drug B for three days (see Methods). Drugs A and B used in combination (like ACTs) had the same  
157 respective profile as in monotherapy, but patients received a daily dosage of each drug over three days,  
158 as recommended by WHO for ACTs [56]. (B) Curves illustrate examples of the modelled relationship  
159 between the concentration (log(mg/l)) and the killing effect (per day) of drugs A and B on the resistant  
160 (brown) and sensitive genotypes (blue). For the use of drugs in combination, the resistant genotype was  
161 resistant to drug A, and both sensitive and resistant genotypes could have some degree of resistance  
162 to drug B. (C) The orange area highlights steps that evaluate how the probability of establishment of  
163 mutations with a specific selection coefficient varies under different settings. The purple area highlights  
164 the steps for assessing the influence of factors on the rate of spread (selection coefficient) of a resistant  
165 genotype through global sensitivity analysis. The brown curve represents an example of the relative  
166 frequency of the resistant genotype in infected humans. HGP: Heteroskedastic Gaussian Process.



167 **Table 1**

168 **Potential drivers of the spread of drug resistance.**

169 List of factors and their parameter ranges investigated in the global sensitivity analyses of the spread of  
 170 parasites resistant to each treatment profile. The parameter ranges were defined based on the literature  
 171 as described in the Methods. Parameter ranges of drug A captured the parameter values of typical  
 172 artemisinin derivatives (see Methods). The parameter ranges of drug B captured the parameter values  
 173 of partner drugs of artemisinin derivatives such as mefloquine, piperaquine, and lumefantrine (see  
 174 Methods). Note that the ratio Cmax/EC50 is not a direct input of the model, but we varied this ratio by  
 175 varying the EC50 of the sensitive genotype and the drug dosage (which impacted the maximum drug  
 176 concentration (Cmax)) (see Methods). A Latin Hypercube Sampling (LHS) algorithm was used to sample  
 177 from the ranges [57].

Component	Determinant	Definition	Parameter range	
			Drug A	Drug B
<b>Drug properties</b>	Half-life	Time for the drug concentration to fall by 50% (days)	(0.035, 0.175)	(6, 22)
	Emax	Maximum killing rate the drug can achieve (per day)	(27.5, 31.0)	(3.45, 5.00)
	Cmax/EC50	The ratio between the maximum drug concentration (Cmax) and the half-maximal effective concentrations (EC50) of the sensitive genotype. This calculated ratio captures the drug killing effect by capturing how high is the Cmax compared to the EC50.	(55.0–312.0)	(5.1–21.7)
<b>Parasite biology</b>	Degree of resistance	For drug A: relative decrease of the Emax of the resistant genotype compared with the sensitive one For drug B: relative increase of the EC50 of the resistant genotype compared with the sensitive one (see Methods)	(1, 50)	(1, 20)
	Fitness cost	Relative reduction of the resistant genotype multiplication rate within the human host compared to the sensitive one	(1.0, 1.1)	
<b>Transmission level</b>	Entomological inoculation rate	Mean number of infective mosquito bites received by an individual during a year (inoculations per person per year)	(5, 500)	
<b>Health system</b>	Level of access to treatment	The probability of symptomatic cases to receive treatment within two weeks from the onset of symptom onset (%)	(10, 80)	
	Diagnostic detection limit	Parasite density for which the probability of having a positive diagnostic test is 50% (parasites/μl)	(2, 50)	

## 178 **Key drivers of the spread of drug-resistant parasites**

179 Under monotherapy, access to treatment and degree of resistance of a monotherapy were the  
180 main drivers of the spread of resistance (Figure 2A). For drugs A and B used as monotherapy,  
181 the selection coefficient increased with increasing access to treatment (the probability of  
182 symptomatic cases to receive treatment within two weeks from the onset of symptoms) (Figure  
183 S1). In addition, higher degrees of resistance of the resistant genotype to drug A (relative  
184 decrease in the resistant genotype  $E_{max}$  compared with the sensitive one) and B (relative  
185 increase in the resistant genotype  $EC_{50}$  compared with the sensitive one) promoted the spread  
186 of parasites resistant to drugs A and B, respectively (Figure S1).


187 When drugs A and B were used in combination, we assumed the resistant genotype had some  
188 degree of resistance to drug A, but both the sensitive and resistant genotypes could have some  
189 degree of resistance to drug B. In this case, the most important driver of spread was the degree  
190 of resistance of both genotypes to drug B (Figure 2A). The median selection coefficient was  
191 below zero when both genotypes were susceptible to drug B (the minimum degree of  
192 resistance to drug B) (Figure 2B), indicating that using an efficient partner drug can limit the  
193 spread of artemisinin resistance. The spread of parasites resistant to drug A was accelerated  
194 when parasites were also resistant to the partner drug, highlighting that resistance to the  
195 partner drug can facilitate the spread of artemisinin resistance. We further illustrated with  
196 concrete examples (Supplementary file 1: section 1.2) how the spread of partial resistance to  
197 drug A accelerates with higher degrees of resistance to drug B. These results further confirmed  
198 that resistance to partner drugs facilitates the spread of resistance to artemisinin, highlighting  
199 the importance of combining artemisinin derivatives with an efficient partner drug.



200 **Figure 2**

201 **Influence of drug properties, fitness costs, resistance levels, transmission levels, and health**  
202 **system factors on predicted selection coefficients for three treatment profiles.**

203 (A) The first-order indices from our variance decomposition analysis indicate the level of importance of  
204 drug properties, fitness costs, resistance levels, transmission levels, access to treatment, and diagnostic  
205 limits in determining the spread of drug resistance. Indices are shown for each treatment profile in a  
206 non-seasonal setting with a population fully adherent to treatment. Selection coefficients are considered  
207 for drug A and drug B when each drug is used as monotherapy and for drug A when both drugs are  
208 used in combination. Definitions and ranges of parameters investigated are listed in Table 1. (B)  
209 Influence of factors on the selection coefficient of genotypes resistant to drug A in a population that used  
210 drugs A and B in combination. Curves and shaded areas represent the median and interquartile range  
211 of selection coefficients estimated during the global sensitivity analyses over the following parameter  
212 ranges: access to treatment (10–80%); the degree of resistance of the resistant genotype to drug A  
213 (1–50-fold reduction in Emax); and the degree of resistance of both sensitive and resistant genotypes  
214 to drug B (1–20-fold increase in EC50). A selection coefficient below zero implies that resistance does  
215 not spread in the population but is being lost due to its fitness costs. The transmission setting was non-  
216 seasonal and, all treated individuals were fully adherent to treatment.



## 217 **Variation in the influence of factors across settings and degrees of resistance**

218 We compared the effects of drug properties and fitness cost on the selection coefficients for a  
219 fixed set of degrees of resistance, transmission levels, seasonality patterns, treatment levels,  
220 and levels of adherence to treatment (percentage of treatment doses adhered by patients)  
221 (see the legend of Figure 3 for the values of each fixed factor). Across settings with a low  
222 access to treatment, we found that fitness cost had the largest influence on the selection  
223 coefficient (Figure S2-5). The fitness cost of a resistant genotype was defined as the relative  
224 decrease in the resistant genotype multiplication rate within an untreated human host  
225 compared with the sensitive genotype. Consequently, high fitness costs prevented the spread  
226 of resistance (Figure S2). At a high level of access to treatment, drug properties played a  
227 critical role in the spread of drug resistance, and their influence varied for each treatment profile  
228 as described below (Figure 3, Figure S3-5).

229 For drug A used as monotherapy, the half-life had the biggest influence on the rate of spread  
230 (Figure 3, Figure S3). A long half-life reduced the spread of resistant parasites by extending  
231 the period during which the drug killed partially resistant parasites (Figure 3). Furthermore, the  
232 spread of the resistant genotype was faster in populations with low adherence to treatment  
233 (Figure 3–Figure S6) because with fewer treatment doses, the parasite was exposed to the  
234 drug for a shorter time, leading to higher parasite survival. Overall, these results highlight that  
235 the time during which the parasite is exposed to artemisinin is a critical driver of the spread of  
236 partial artemisinin resistance.

237 For parasites resistant to drug B when used as monotherapy, the drug half-life also had an  
238 important influence on the selection coefficient (Figure 3, Figure S4). However, long half-lives  
239 were associated with large selection coefficients (Figure 3). Drugs with a long half-life have an  
240 extended period of low drug concentration in treated patients during which only resistant  
241 parasites can infect the host. This period of low drug concentration is called the selection  
242 window [49, 58]. These results confirm that the selection window plays a crucial role in the  
243 spread of resistance to long-acting drugs.

244 In addition, for parasites resistant to drug B as monotherapy, the drug killing rate captured by  
245 the ratio  $C_{max}/EC_{50}$  had an important influence on the rate of spread in settings with low level  
246 of treatment adherence or a high degree of resistance (Figure 3, Figure S4). When we  
247 modelled a low level of treatment adherence or a high level of resistance, this ratio was  
248 reduced due to lower  $C_{max}$  or higher  $EC_{50}$ , respectively. Lower  $C_{max}/EC_{50}$  ratios cause  
249 lower drug killing rates, and when this ratio was too low the spread of drug resistance was  
250 favoured. These results highlight the importance of treatment adherence to assure that the  
251 drug concentration is high enough to eliminate partially resistant genotypes and limit their  
252 spread.

253 When the genotype was resistant to drug A in a population that used drugs A and B in  
254 combination, factors related to drug B had the most influence on the selection coefficient  
255 (Figure 3, Figure S5). When the ratio  $C_{max}/EC_{50}$  or the half-life of drug B was large, the killing  
256 effect of drug B on parasites resistant to drug A was higher, reducing their spread (Figure 3).  
257 In addition, the rate of spread rose when the level of adherence to treatment was low (Figure  
258 S6). These results highlight that the spread of partial resistance to artemisinin strongly depends  
259 on the capacity of the partner drug to kill them.


260 The influence of the transmission intensity (represented by EIR) and its seasonality on the  
261 selection coefficient varied by treatment profiles. When the parasite was resistant to drug A  
262 when used as monotherapy or in combination with drug B, selection coefficients were higher  
263 in settings with lower EIR (Figure S6). Two factors account for this trend. First, the selection of  
264 parasites resistant to drug A depends on the proportion of infections that are treated and can  
265 thus select for resistance. This proportion is higher at lower EIR due to the lower level of  
266 immunity (Figure S7) which makes infections more likely to be symptomatic and hence receive  
267 treatment. Second, there is a high multiplicity of infection in high transmission settings. The  
268 multiplicity of infection enhanced within-host competition between genotypes, which inhibit the  
269 multiplication of resistant parasites within hosts due to their fitness cost, and thus limit their  
270 spread. Similarly, the spread of resistant parasites was higher in the seasonal settings than in  
271 non-seasonal settings (Figure S6) due to the reduction of immunity levels and a decline in  
272 within-host competition between genotypes during the low transmission season of the  
273 seasonal settings. Overall, these results indicate that the spread of partial artemisinin  
274 resistance is faster in seasonal settings with low transmission levels.

275 However, for parasites resistant to drug B used in monotherapy, selection coefficients were  
276 higher in settings with a large EIR (Figure S6). This relationship arises because resistant  
277 parasites are more likely to emerge from the liver in high transmission settings during selection  
278 window (which select for resistant parasites). This is because the proportion of people treated  
279 (and thus with residual drug concentrations) is lower at lower EIR due to lower infection rates  
280 (Figure S7). Note that this trend was only valid for settings with high access to treatment. In  
281 settings with low access to treatment, we observe similar trends than for parasites resistant to  
282 drug A (Figure S8) since here, the impact of the selection window was more negligible. These  
283 results highlight that the selection window of the long-acting drug can change the interplay  
284 between the transmission setting and the spread of drug resistance.

285 **Figure 3**

286 **Magnitude and direction of effect of drug properties and fitness cost on predicted selection**  
 287 **coefficients for low and high levels of transmission, degrees of drug resistance, treatment**  
 288 **adherence, in seasonal or perennial settings with monotherapy or combination treatment.**

289 The curves represent median selection coefficients over the parameter ranges estimated in each setting  
 290 that had high access to treatment (80%) and an entomological inoculation rate (EIR) of 5 (solid curves)  
 291 or 500 (dashed curves) inoculations per person per year. Settings were varied in their seasonality  
 292 pattern of transmission and level of adherence to treatment (67% (low) or 100% (high) of treatment  
 293 doses adhered to by the population). For each treatment profile, results are shown for parasites with  
 294 two different degrees of resistance; degree of resistance of 7 (low) and 18 (high) to drug A (Emax shift),  
 295 2.5 (low) and 10 (high) to drug B (EC50 shift), for the combination of drugs A and B, 7 (low) and 18  
 296 (high) to drug A and 10 to drug B. Parameter ranges are as follows: fitness cost (1.0–1.1, light green  
 297 curves); drug A half-life (0.035–0.175 days, pink curves); drug B half-life (6–22 days, purple curves);  
 298 Cmax/EC50 ratio for drug A (55.0–312.0, blue curves); Cmax/EC50 ratio for drug B (dark green curves)  
 299 at a high level of adherence to treatment (5.4–21.7) and at a low level of adherence (4.0–16.2).



300 **Probability of establishment of drug resistance and its key drivers**


301 In each non-seasonal setting, we selected 10 different resistant genotypes having a known  
302 selection coefficient and quantified their probability of establishment (see Methods). By doing  
303 so, we evaluated the relationship between the selection coefficient and probability of  
304 establishment and assessed how this relationship varies across settings due to variation in the  
305 heterogeneity of parasite reproductive success.

306 As expected, the establishment of a mutation was more probable when its selection coefficient  
307 was high (Figure 4). For each treatment profile, the probability of establishment of mutations  
308 with similar selection coefficients was higher at low EIR than at high EIR (Figure 4), especially  
309 for mutations with a high selection coefficient. These results highlight that the heterogeneity in  
310 parasite reproductive success increases with the transmission level, causing more uncertainty  
311 in the establishment of mutations. Two factors increase the heterogeneity of parasite  
312 reproductive success in settings with a high EIR. First, in these settings, there is considerable  
313 variation in the number of independent infections carried by hosts, which are competing for  
314 reproductive success. This variation leads to more heterogeneity of parasite reproductive  
315 success and thus to less certainty that a parasite with an emerging mutation will replicate.  
316 Second, settings with a high EIR have a large variation in the level of individual immunity. Host  
317 immunity influences parasite reproductive success by reducing parasite growth within the  
318 human host. Therefore, in high transmission settings, the greater variation of immunity leads  
319 to higher heterogeneity of parasite reproductive success and a lower probability that an  
320 emerging mutation successfully replicate.

321 **Figure 4**

322 **Predicted probability of establishment of mutations conferring drug resistance across**  
323 **transmission settings.**

324 Solid curves and dashed curves represent the relationship between the selection coefficient and the  
325 estimated probability of establishment of resistant parasites across settings that differ in transmission  
326 intensities (5 and 500 inoculations per person per year, respectively). The range of selection coefficients  
327 include higher values at a low EIR. For each setting, the level of access to treatment was specified as  
328 80%, the population was assumed to be fully adherent to treatment (100%), and transmission was non-  
329 seasonal.



## 330 Discussion

331 Understanding which disease, transmission, epidemiological, health system, and drug factors  
332 systemically drive the evolution of drug resistance is challenging. A full understanding requires  
333 vast observational data or clinical trials on a scale that is not possible or mathematical models  
334 that are sufficiently detailed to capture all these factors while remaining computationally  
335 feasible to simultaneously assess the impact of these factors. In response to this need, we  
336 updated a detailed individual-based model of malaria dynamics to include a full  
337 pharmacological (i.e. PK/PD) description of antimalarial treatments. We introduced a global  
338 sensitivity analysis approach based on emulators for computationally intensive models to  
339 systematically assess which factors jointly drive the evolution of drug-resistant parasites. As  
340 discussed below, our approach allowed us to understand the guiding principles of the evolution  
341 of drug resistance against ACTs and to explain the difference in trends observed in the Greater  
342 Mekong Subregion (GMS) and in malaria endemic Africa. Improving our understanding of the  
343 factors that lead to drug resistance establishment and spread allows us to identify strategies  
344 to mitigate these dynamics and guides initial considerations for developing more sustainable  
345 malaria treatment.

346 Our results support the belief that evolution of resistance to ACTs begins with the  
347 establishment and spread of parasites resistant to the partner drug and, once the protective  
348 effect of the partner drug is reduced, drug selection falls on the artemisinin component, and  
349 parasites then start to acquire resistance to artemisinin derivatives (e.g. [48, 59]). The fact that  
350 resistance to the partner drug appears before resistance to artemisinin derivatives was  
351 supported by two points elucidated in our study. First, resistance to the partner drug strongly  
352 depends on the period of low concentration of this drug during which only resistant parasites  
353 can multiply within the host (known as the selection window). As artemisinin derivatives are  
354 short-acting, they cannot prevent patients from being reinfected by parasites resistant to the  
355 partner drug during this selection window. Second, resistance to the partner drug was the most  
356 critical factor that enhanced establishment and spread of partial artemisinin resistance. Without  
357 resistance to the partner drug, parasites partially resistant to artemisinin could only spread at  
358 a low rate as the partner drug could still eliminate them, thereby removing their selective  
359 advantage. Our results are in line with recent molecular data which show that parasites  
360 resistant to partner drugs (piperaquine and mefloquine) were already present in the GMS  
361 before partial artemisinin resistance emerged and that the spread of resistance to artemisinin  
362 accelerated when it became linked to resistance to the partner drugs [60-62]. Thus, the  
363 presence of partner drug resistance has probably facilitated the spread of resistance to  
364 artemisinin in the GMS. In contrast, in Africa, to date, only a low degree of resistance to the  
365 most commonly used partner drugs (lumefantrine and amodiaquine) are present [2, 63], which  
366 has likely limited establishment of resistance to artemisinin derivatives. We additionally note  
367 that the evolution of drug resistance in the GMS may have been favoured by the low  
368 transmission intensity (annual EIR range approximate from less than 1 to 25 inoculations per  
369 person per year [64-66]) compare to Africa where the transmission intensity is overall higher  
370 (annual EIR range from less than 1 to more than 500 inoculations per person per year [67,  
371 68]). Similar to previous studies [4, 25, 28, 34, 69], establishment of drug resistance in our  
372 model was more likely in low transmission settings due to the reduced level of within-host  
373 competition between genotypes, as well as population immunity.

374 Our results suggest that a key strategy to mitigate the evolution of partial artemisinin resistance  
375 is to ensure that the partner drug efficiently kills the partially resistant parasite. Therefore, to

376 delay the establishment of artemisinin resistance in Africa and to mitigate the spread of partial  
377 artemisinin resistance in regions where it is already established, we should ensure that limited  
378 or no genotypes are resistant to the partner drug for first-line ACT. One approach to ensure  
379 this is to implement robust molecular surveillance of resistance markers and to specify more  
380 sustainable treatment policies, such as changing first-line ACTs upon detection of resistance  
381 or when the frequency of resistant parasites reach a threshold as recommended by the WHO  
382 [2]. Furthermore, consistent with our results, adherence should continue to be promoted, as  
383 lower treatment compliance can lead to treatment failure even in the absence of resistance to  
384 the partner drug [2, 70, 71].

385 Our results suggest that future antimalarial therapies should shorten the selection windows of  
386 long-acting partner drugs. We show that resistance to long-acting drugs (drug B) is the first  
387 step in the evolution of resistance to ACTs, and it depends mainly on the length of the selection  
388 window. We confirm that the selection window strongly depends on the drug half-life, also  
389 consistent with previous studies [4, 23, 27, 28, 49, 58]. Consequently, reducing the half-life of  
390 the partner drug in an ACT regimen could reduce the spread of resistance. However, unless  
391 selection windows are substantially minimised or completely eliminated, the evolution of  
392 resistance would not totally be prevented [58]. Thus, a more sustainable option for ACTs would  
393 be to use triple artemisinin-based combination therapies (TACTs). TACTs involve combining  
394 an artemisinin derivative with two long-acting drugs [72].

395 If or when TACTs are to be widely used, our results emphasize that the two long-acting drugs  
396 should have matching half-lives to ensure that parasites are not exposed to residual drug  
397 concentrations of only one of the two partner drugs (noting that this is simple in principle, but  
398 more difficult in practice [73]). In addition, the parasite population should be devoid of parasites  
399 resistant to either of the two long-acting drugs. If resistance to one partner drug already exists  
400 in the population, the second partner drug would not be protected, and mutations conferring  
401 resistance to this second drug would be selected. Thus, ideally, we should avoid combining  
402 previously used long-acting drugs (because resistance to these drugs may already be  
403 present), and rather favour two partner drugs not routinely in use, and preferably having a new  
404 mechanism of action. Therefore, selecting drugs to combine for TACTs requires balancing the  
405 need to mitigate resistance against the development time of new partner drugs. Note that the  
406 development of new partner drugs for TACTs may be challenging because combining three  
407 drugs is likely to increase the risk of toxicity and the treatment price, and future antimalarial  
408 medicines must remain tolerated by patients and affordable [72].

409 Another approach to delay the evolution of partial artemisinin resistance could focus on  
410 extending the period of action of artemisinin derivatives. In our monotherapy analysis on the  
411 spread of a genotype partially resistant to artemisinin, we found that the spread of partially  
412 resistant genotypes decreased when the drug was present in patients for a longer time, such  
413 as if it had a long half-life and there was proper treatment adherence. This result arises  
414 because partially resistant parasites are still affected by the drug [40, 42-44]. Thus, increasing  
415 their exposure to the drug leads to higher killing and reduced spread. Increasing the exposure  
416 to artemisinin derivatives can be achieved by using the artemisinin derivative having the  
417 longest half-life and, as highlighted in other studies [74-76], can be done by increasing the  
418 number of doses and days that patients receive treatment. However, it is worth noting that  
419 extending the dosage regimen will be efficient only with adequate adherence to treatment,  
420 which may be challenging to achieve in practice. Also, as artemisinin derivatives are co-  
421 administered with at least one long-acting drug, increasing the number of doses of this



422 combination therapy would require reducing the concentration of the partner drug to prevent  
423 the partner drug from reaching toxic concentrations.

424 The evolution of drug resistance is a three-step process consisting of mutation, establishment,  
425 and spread. Mutation rates in malaria can easily be measured, and spread, quantified by the  
426 selection coefficient, is also easy to measure. However, the probability of establishment and  
427 its relation to the selection coefficient constituted a significant knowledge gap. Standard  
428 population genetic models assume that the number of secondary infections follows a Poisson  
429 distribution [15, 77]. Under this assumption, for selection coefficients lower than 0.2 (according  
430 to an informal literature review in [16], most selection coefficient estimates for malaria drug  
431 resistance mutations from the field fall between 0.02 to 0.12), the probability of establishment  
432 is approximately equal to twice the selection coefficient [15, 77]. However, the number of  
433 secondary malaria infections more likely follows a negative binomial distribution due to the high  
434 heterogeneity of transmission, which may substantially reduce the probability of establishment  
435 (Box 2 of [15]). In this modelling study, we were uniquely able to quantify the link between  
436 selection coefficients and the probability of establishment of mutations. On average, we  
437 predicted that, for selection coefficients lower than 0.2, the probability of establishment was  
438 equal to 0.87-times the selection coefficient. Therefore, our findings suggest that the variation  
439 in the number of secondary infections of *P. falciparum* must be much greater than the Poisson  
440 distribution assumed by standard population genetics models, and this higher variation  
441 reduces the probability of establishment of emerging mutations.

442 As with all modelling studies, our approach has several limitations, primarily arising from  
443 constraints imposed by the model. First, our drug action model does not capture stage-specific  
444 killing effects, so we could not model parasites partially resistant to artemisinin being  
445 insensitive to the drug only during extended ring-stage [40, 42-44], although previous analyses  
446 suggested this would be captured by our variation in the maximum killing rate [78].  
447 Nevertheless, if we modelled a reduction of the drug effect restricted to the ring-stage, we  
448 expect to obtain similar results. That is, a long half-life and high treatment adherence would  
449 increase the likelihood that the drug is present within patients during any stage other than the  
450 ring-stage, and thus the drug would kill more resistant parasites.

451 Second, our model did not capture the impact of artemisinin resistance on gametocytes.  
452 Previous studies have highlighted that artemisinin kills gametocytes, and patients infected with  
453 parasites partially resistant to artemisinin exhibit higher gametocyte densities than patients  
454 infected with sensitive parasites [79, 80]. We did not model the impact of artemisinin and  
455 resistance on gametocytes. This effect is likely to accelerate the spread of partial resistance.  
456 However, the relationship between the different factors reported in this study should be  
457 unchanged.

458 Third, our model, OpenMalaria, does not capture the recombination of *P. falciparum* parasites  
459 in mosquitoes. Currently, OpenMalaria does not support chromosomal recombination as it  
460 does not track the different genotypes in mosquitoes, and the genotype of new infections is  
461 based on the genotype frequency in humans. Previous models have shown that if multiple  
462 mutations are needed to confer drug resistance, recombination could slow the evolution of  
463 drug resistance by separating these mutations, especially in settings with a high rate of  
464 infection [69, 81]. We ignored the effect of recombination by assuming that only one mutation  
465 differs between the resistant and sensitive genotypes, which is valid for resistance to certain  
466 drugs, such as artemisinin [2, 3]. However, for other drugs, such as sulfadoxine-

467 pyrimethamine, drug resistance is due to the accumulation of multiple mutations in two genes  
468 [82].

469 Lastly, to investigate the establishment of drug-resistant parasites, we modelled the  
470 emergence of mutations through importation. Consequently, our estimations represent the  
471 establishment of mutations imported into a population or mutations emerging in mosquitoes  
472 (assuming that the mosquito has only transmitted the mutated genotype and not the wild type  
473 genotype to the individual). A mutation emerging during the blood-stage within the human host  
474 may have a lower probability of establishment because sensitive parasites would be present  
475 in the host, leading to competition between them. It is still unclear whether mutations conferring  
476 drug resistance arise during the blood-stage (due to the high parasite numbers) or during the  
477 sexual stage in mosquitoes (because recombination generates many genetic variations).  
478 Nevertheless, the probabilities of establishment estimated in this study are consistent with the  
479 probabilities of establishment predicted by a previous study [15].

480 In summary, our results confirm that mutations conferring malaria drug resistance are more  
481 likely to establish in low transmission settings. Our results demonstrate that the establishment  
482 and spread of resistance to artemisinin derivatives have likely been facilitated by pre-existing  
483 resistance to partner drugs. Thus, it is essential to prioritise monitoring and to limit the spread  
484 of resistance to partner drugs in current or future ACT regimens. If resistance to the partner  
485 drug is confirmed, response strategies should prioritise monitoring molecular markers and  
486 treatment failure and switching to an ACT with an effective partner drug should be considered.  
487 In addition, our results show that drug properties play an essential role in the evolution of  
488 parasite drug resistance. Thus, the ongoing development of new antimalarial combinations  
489 should limit selection windows of partner drugs by matching half-lives, hopefully leading to  
490 longer lasting combination treatments against malaria. In the medium-term, for existing ACTs,  
491 it would be advantageous to increase the time of parasite exposure to the short-acting  
492 artemisinin derivate and/or to include a second long-acting partner drug with a matching half-  
493 life to the other long-acting partner drug (triple ACTs [72]) and for which limited or no parasite  
494 resistance exists in the target population.

## 495 **Methods**

### 496 **Simulation model and the parameterisation of treatment profiles and resistant** 497 **genotypes**

#### 498 *(i) Overview of our OpenMalaria model*

499 Our individual-based model, OpenMalaria, simulates the dynamics of *P. falciparum* in humans  
500 and links it to a periodically forced deterministic model of *P. falciparum* in mosquitoes [83-85].  
501 The model structure and fitting are described in detail elsewhere [84, 85], including open-  
502 access code (<https://github.com/SwissTPH/openmalaria>) and documentation  
503 (<https://github.com/SwissTPH/openmalaria/wiki>), and a recently published manuscript  
504 provides a new calibration [86]. Here, we have summarised the main components of  
505 OpenMalaria and its latest developments in version 40.1, which enabled us to model the  
506 establishment and spread of drug-resistant parasites.

507 OpenMalaria is an ensemble of models in which mosquito and infection events, and parasite  
508 and human attributes are updated every five days. A demography model maintains a constant

509 human population size and age structure across the simulation. Multiple parasite genotypes  
510 and their initial frequency can be defined in more recent model versions. For each infection, a  
511 mechanistic model simulates the parasite dynamics within the host and incorporates innate,  
512 variant, and acquired immunity [50]. The within-host model allows for concurrent infection of  
513 multiple parasite genotypes within the same host and captures indirect competition between  
514 genotypes based on host immunity, which regulates the overall parasite load. The user can  
515 specify a reduction of the within-host multiplication factors of each genotype to model a fitness  
516 cost associated with the mutation. The host's parasite density determines the symptoms and  
517 mortality of patients and diagnostic test results. The occurrence and severity of patient  
518 symptoms depend on their pyrogenic threshold, which increases (until saturation) with recent  
519 parasite exposure and decays over time [87]. Severe episodes of malaria occur due to a high  
520 parasite density or due to co-morbidities [88]. Malaria mortality can be a consequence of a  
521 severe episode or an uncomplicated episode with co-morbidity [88, 89]. The model also takes  
522 into account neonatal deaths [88, 89]. Immunity to asexual parasites prevents severe cases  
523 by decreasing the parasite multiplication rate within the host. Individual immunity depends on  
524 the cumulative parasite and infection exposure frequency, as well as maternal immunity in their  
525 newborn children for several months [90].

526 The case management component of OpenMalaria describes the use of treatment for  
527 uncomplicated and severe cases and depends on access to health services and whether  
528 patients have previously been treated for the same episode [91]. The disease model includes  
529 explicit pharmacokinetic-pharmacodynamic (PK/PD) models that capture the process whereby  
530 drugs reduce the parasite multiplication rate in treated hosts [51, 54]. Pharmacodynamic  
531 parameters are parameterised individually for each genotype to allow different degrees of drug  
532 susceptibility to be modelled.

533 The entomological component of OpenMalaria simulates the mosquito vector feeding  
534 behaviours and tracks the infectious status of mosquitoes [83]. The periodicity of this model  
535 allows seasonal patterns of transmission to be captured. The probability that a feeding  
536 mosquito becomes infected depends on the parasite density within bitten individuals [92]. No  
537 recombination is modelled between the different genotypes in the mosquitoes. The number of  
538 newly infected hosts depends on the simulated entomological inoculation rate (EIR) of the  
539 vector model [83]. The genotype of new infections is based on the genotype frequencies in  
540 humans from the previous five time steps [92].

#### 541 *(ii) Parameterisation of the treatment profiles*

542 This study investigated factors influencing the establishment and spread of parasites resistant  
543 to three different treatment profiles.

544 The first treatment profile modelled was a short-acting drug administered as monotherapy,  
545 referred to as drug A. Drug A has a short half-life and a high killing efficacy, simulating  
546 artemisinin derivatives (Figure 1A and 1B). We modelled the pharmacokinetics of drug A using  
547 a one-compartment model, which is considered sufficient when modelling short-acting  
548 antimalarials [52, 54]. We varied key PK/PD parameters (half-life, EC50, Emax) in the global  
549 sensitivity analysis to assess their influence on the rate of spread of resistance. The EC50  
550 ranged from 0.0016 to 0.009 mg/l to include the EC50 of artemether, artesunate, and  
551 dihydroartemisinin [52, 54]. The half-life parameter ranges represented the values for  
552 artemether, artesunate, and dihydroartemisinin used by [52, 54] (Table 1). Note that in [52],  
553 the Emax of all short-acting drugs was equal to 27.6 per day. However, we varied the killing

554 rate and included higher values to investigate its effects on the rate of spread (Table 1). To  
555 ensure that drug A killed the sensitive parasites efficiently for any combination of parameters,  
556 we extended the treatment course from a daily drug dose for three days to a daily drug dose  
557 for six days. Moreover, we parameterised the dosage and constant parameter values to that  
558 for dihydroartemisinin (Table S1), as it is the artemisinin derivate with the shortest elimination  
559 half-life and highest EC50 [52, 54]. By doing so, we also ensured that drug A had the typical  
560 profile of an artemisinin derivative.

561 The second treatment profile modelled was a long-acting drug administered as monotherapy,  
562 referred to as drug B. Drug B had a long half-life and a lower Emax than drug A (Figure 1A  
563 and 1B), typical of partner drugs used for ACTs. We modelled the PK of drug B with a two-  
564 compartment model, which is more typical of the clinical PK of partner drugs [51]. As for drug  
565 A, key PK/PD parameters (half-life, EC50, Emax, and dosage) were varied in the global  
566 sensitivity analysis. The EC50 ranged from 0.01 to 0.03 mg/l to include the EC50 of mefloquine,  
567 piperaquine and lumefantrine used by [52, 54]. The half-life range corresponded to the value  
568 reported for mefloquine, piperaquine, lumefantrine in [93-97] (Table 1). We increased the  
569 Emax range from 3.45 per day (as reported in [54]) to 5.00 per day to investigate the effect on  
570 the rate of spread (Table 1). We also assessed the impact of Cmax on the rate of spread for  
571 drug B because the Cmax varies between ACTs partner drugs and has a strong influence on  
572 the post-treatment killing effect of drug B [73]. We varied drug dosage from 30 to 40 mg/kg to  
573 examine the influence of variation of Cmax on the spread rate for drug B. The lower limit of 30  
574 mg/kg was fixed to ensure that drug B killed the sensitive genotype efficiently for any parameter  
575 combination. The treatment course involved a daily drug dose for three consecutive days. To  
576 ensure that drug B had the profile of typical partner drugs, the values of the constant  
577 parameters were parameterised to the values of piperaquine reported in [54, 94] (Table S2).

578 The last treatment profile was a combination of drugs A and B, simulating ACT. We tracked  
579 the concentration of each drug independently. We used the same models, parameter values  
580 and ranges for the two drugs as when both drugs were used as monotherapy. However, the  
581 treatment course involved a daily dose of both drugs for three days, as recommended by the  
582 WHO for most ACTs [56]. In OpenMalaria, the killing effects of the two drugs were calculated  
583 independently and acted simultaneously on the parasites.

### 584 *(iii) Parameterisation of the drug-resistant genotypes*

585 For each simulation, we tracked two genotypes, one drug-resistant and one drug-sensitive.  
586 We investigated the spread of resistant parasites with different degrees of resistance (Table  
587 1). We modelled the phenotype of drug resistance and the degree of resistance differently for  
588 each drug profile.

589 Previous studies have shown that parasites partially resistant to artemisinin exhibit an  
590 extended ring-stage during which they are not sensitive to artemisinin (even at high drug  
591 concentrations) but remain sensitive to the drug during other stages of the blood replication  
592 cycle [40-44]. OpenMalaria does not model the specific drug-killing effect for the different steps  
593 of the blood-stage. As in [98, 99], we assumed that parasites resistant to drug A had a reduced  
594 Emax compared with sensitive ones (Figure 1B). This assumption captured the fact that,  
595 overall, drug A killed fewer resistant parasites than sensitive ones at any drug concentration  
596 because they are not sensitive to artemisinin during the ring-stage and that this stage-specific  
597 effect is best incorporated into PK/PD modelling by variation in Emax [78].

598 Previous studies reported that parasites resistant to long-acting drugs typically have an  
599 increased EC50 [45-47]. Thus, as in other models, we defined parasites resistant to drug B to  
600 have a higher EC50 than the sensitive ones (Figure 1B) [52, 54]. With an increased EC50, the  
601 resistant parasites were less susceptible to the drug at low drug concentrations. Thus, these  
602 resistant genotypes were more likely to survive drug treatment and are more likely to  
603 successfully infect new hosts with higher residual drug concentrations [58].

604 Considering drugs A and B in combination, the resistant genotype was resistant to drug A. But  
605 in the global sensitivity analysis, both the sensitive and resistant genotypes could have some  
606 degree of resistance to drug B. The decreased susceptibility to drug B was the same for both  
607 sensitive and resistant genotypes, meaning that we assumed the two genotypes differed only  
608 in one mutation, which conferred resistance to drug A. This assumption allowed us to ignore  
609 the effect of recombination in the mosquitoes. In effect, this assumed that the allele defining  
610 the level of resistance to drug B was fixed in the population.

### 611 **Approach to identify the key drivers of the spread of drug-resistant parasites**

612 Through global sensitivity analyses, we quantified how the factors in Table 1 influenced the  
613 spread of drug-resistant parasites for each treatment profile. First, we estimated the effect of  
614 each factor in a non-seasonal setting with a population fully adherent to treatment. Based on  
615 these results, we identified specific settings for further analysis. We performed additional  
616 constrained sensitivity analyses to investigate the impact of varying drug properties and fitness  
617 costs in a fixed set of settings (i.e. in low and high transmission settings, with low and high  
618 treatment levels of monotherapy or combination therapy) and with a fixed degree of resistance.  
619 In this secondary analysis, we also investigated the effect of drivers in seasonal transmission  
620 settings (Figure S10) and where populations adhere to either 100% or 67% of treatment doses.

621 Due to the computational requirements for a large number of simulations of OpenMalaria, and  
622 the number of factors investigated, it was not feasible to simulate either a full-factorial set of  
623 simulations to perform a multi-way sensitivity analysis, or to perform a global sensitivity  
624 analysis. Therefore, we trained a Heteroskedastic Gaussian Process (HGP) [100] on a set of  
625 OpenMalaria simulations and performed global sensitivity analyses using this emulator (Figure  
626 1C), adapting a similar approach to [101] and [86]. Our approach involved: (i) randomly  
627 sampling combinations of parameters; (ii) simulating and estimating the rate of spread of the  
628 resistant genotype for each parameter combination in OpenMalaria; (iii) training an HGP to  
629 learn the relationship between the input (for the different drivers) and output (the rate of spread)  
630 with iterative improvements to fitting through adaptive sampling, and (iv) performing a global  
631 sensitivity analysis based on the Sobol variance decomposition [70]. Each step of the workflow  
632 is detailed below.

#### 633 *(i) Randomly sample combinations of parameters*

634 We randomly sampled 250 different parameter combinations from the parameter space shown  
635 in Table 1 using a Latin Hypercube Sampling (LHS) algorithm [57]. The parameter ranges were  
636 defined as follows. We defined the ranges for the properties of drug A and drug B to include  
637 the typical parameter values of artemisinin derivatives and a long-acting partner drug,  
638 respectively [52, 54, 93-97]. The range of the degree of resistance captured the spread of drug-  
639 resistant parasites, which vary from fully sensitive to having almost no drug sensitivity. The  
640 fitness costs were extracted from studies investigating the decline of chloroquine-resistant  
641 parasites after the drug pressure was removed [102, 103]. The variation in annual EIR captured



642 settings with low transmission to those with high transmission. The range of access to  
643 treatment captured settings with low to high 14-days effective coverage. The values of the  
644 diagnostic detection limit captured the sensitivity of typical diagnostics used for malaria (rapid  
645 diagnostic test, microscopy, and polymerase chain reaction (PCR)) [104, 105].

646 *(ii) Simulate and estimate the rate of spread of the drug-resistant genotype*

647 We quantified the rate of spread through the selection coefficient, a measure widely used in  
648 population genetics to assess the strength of selection on a genotype [16]. The selection  
649 coefficient is the rate at which the logit of the resistant genotype frequency increases each  
650 parasite generation and should be linear throughout the spread [16]. Population genetics  
651 theory often assumes an infinite population size to remove stochastic fluctuation of the allele  
652 frequency, also called genetic drift [16]. However, in our model the parasite population size is  
653 finite, so stochastic fluctuations of the genotype frequency are present. Thus, we should avoid  
654 estimating the selection coefficient when there is a low frequency of the resistant genotype  
655 (from a small human population size, a low EIR, and a small initial frequency of the resistant  
656 genotype) because the resistant genotype may become extinct due to the stochastic  
657 fluctuation. In addition, the effects of genetic drift that occurs when a genotype is present at a  
658 low frequency may cause non-linearity during resistance spread which may obscure the  
659 estimation of the selection coefficient [16].

660 Following the approach described in [16], we assumed an initial percentage of infected humans  
661 carrying the resistant genotype of 50%. A high initial percentage minimises the impact of  
662 random fluctuation on our estimation, and the subsequent risk of extinction, without affecting  
663 our estimate because the selection coefficient was not frequency-dependent (Figure S11). We  
664 simulated the spread of resistant parasites in a human population of 100,000 individuals with  
665 an age structure of a typical African country [106]. We ran each parameter combination on five  
666 stochastic realisations. The simulation started with a burn-in period of 100 years to reach the  
667 expected level of immunity in the population and an additional 30 years to reach EIR  
668 equilibrium (Figure S12). Both genotypes were sensitive to the drug during this period, so the  
669 percentage of infected humans carrying the resistant genotype remained stable. After the burn-  
670 in period, we introduced the fitness cost and the drug for which the resistant genotype had  
671 reduced sensitivity. We then estimated the selection coefficient,  $s$ , as,

672

$$673 \quad s = \frac{1}{t} \left( \ln \left( \frac{p(t+1)}{1-p(t+1)} \right) - \ln \left( \frac{p(1)}{1-p(1)} \right) \right) = \frac{1}{12} \left( \ln \left( \frac{p(13)}{1-p(13)} \right) - \ln \left( \frac{p(1)}{1-p(1)} \right) \right),$$

674

675 where  $p(t)$  is the relative frequency of the resistant genotype in inoculations,  $t$  is the number of  
676 parasite generations after introducing the new drug at  $t = 0$ . We assumed that a parasite  
677 generation is two months (60 days) as in [16]. We started the regression at one parasite  
678 generation after introducing the new drug (at 60 days). We stopped the regression 12  
679 generations later, at 720 days, because, as shown in [16], it was computationally convenient  
680 and returned stable selection coefficient estimates. The regression was stopped sooner if the  
681 relative frequency of inoculations carrying the resistant genotype was higher than 90% or lower  
682 than 30% to prevent tracking a small number of a single genotype for which genetic drift is  
683 strong. In seasonal settings, the rate of spread of the resistant genotype varied throughout the  
684 year. Consequently, we estimated the selection coefficient using a moving average of the

685 relative frequency of the resistant genotype in inoculations (Figure S13). This method  
686 prevented biasing the selection coefficient according to the period included in the regression.

687 Once the selection coefficient was estimated, it could be converted to the number of parasite  
688 generations needed for the relative frequency of the resistant genotype in inoculations to  
689 increase from  $p(1)$  to  $p(t)$ ,

690 
$$t = \frac{1}{s} \left( \ln \left( \frac{p(t+1)}{1-p(t+1)} \right) - \ln \left( \frac{p(1)}{1-p(1)} \right) \right).$$

691 We could then convert the number of parasite generations to time in years, a more relevant  
692 public health measure than the selection coefficient itself.

### 693 *(iii) Train the emulator and improve its accuracy*

694 We randomly split our data into a training dataset containing 80% of simulations and a test  
695 dataset containing 20% of simulations. We trained the Heteroskedastic Gaussian Process  
696 (HGP) on the training dataset using the function `mleHetGP` from the R package 'hetGP' [100].  
697 To assess the accuracy of the emulator, we predicted the selection coefficient for the test  
698 dataset with the emulator and compared these predictions with the expected selection  
699 coefficient estimated using OpenMalaria. We iteratively improved the accuracy of our emulator  
700 through adaptive sampling. Adaptive sampling involved resampling 100 parameter  
701 combinations in the parameter space where we were less confident (higher variation) in the  
702 HGP prediction and repeating the entire process until the emulator had a satisfactory level of  
703 accuracy. The satisfactory level of accuracy was defined based on the correlation coefficient  
704 and the root means squared error of the predicted selection coefficient and expected selection  
705 coefficient (Figure S14-20).

### 706 *(iv) Global sensitivity analysis*

707 Using the emulator, we undertook global sensitivity analyses using Sobol's method [107]. This  
708 method attributed fractions of the selection coefficient variance to each input [107]. We  
709 performed the global sensitivity analysis using the function `soboljansen` from the R package  
710 'sensitivity' [108], and two random datasets with a sample size of 100,000, with 150,000  
711 bootstrap replicates. With this function, we estimated first-order and total Sobol' indices  
712 simultaneously. The first-order indices represent contributions of each parameter's main effect  
713 to the model output variance. The total effect represents the contribution of each parameter to  
714 the model output variance considering their interactions with other factors. We report only the  
715 first-order indices in the Results section because we did not observe many interactions  
716 between these factors. Some parameters supported the spread of resistance (increased the  
717 selection coefficient), whilst others hindered the spread (decreased the selection coefficient).  
718 To visualise the direction of the effect of each parameter, we calculated the 25th, 50th, and  
719 75th quantiles of the predicted selection coefficient over the corresponding parameter ranges.

## 720 **Establishment of drug resistance**

721 As explained in the Introduction, the establishment of resistant mutations is a stochastic  
722 process that depends on the selection coefficient of the mutation and the heterogeneity of  
723 parasites reproductive success in the setting, which in turn depends on the transmission level  
724 and the health system strength [13, 15-18]. Estimating the probability of establishment requires  
725 running many stochastic realisations due to the stochasticity of this step. To be more

726 computationally efficient, we assessed the probability of establishment of a subset of 10  
 727 resistant genotypes with a known selection coefficient per setting and treatment profile. Based  
 728 on the observed relationships between the selection coefficient and the probability of  
 729 establishment for each treatment profile and setting, we could then extrapolate the probability  
 730 of establishment of any mutations having a known selection coefficient.

731 To estimate the probability of establishment, we modelled the emergence of resistant  
 732 mutations in a fully susceptible population. We used the approach described in [16] in which  
 733 resistant infections were imported into the population at a low rate. In OpenMalaria, imported  
 734 infections have the same frequencies of genotypes as in initialisation, thus we cannot import  
 735 only resistant infections. Therefore, to import resistant infections in a population infected only  
 736 by sensitive parasites, we followed the step described below (Figure S21). We first defined a  
 737 50% relative frequency of resistant parasites in infected humans. The simulation started with  
 738 a burn-in phase of 100 years, during which both genotypes were sensitive to treatment. This  
 739 meant that the relative frequency of the resistant parasites was stable (at 50%). In the second  
 740 phase, we introduced a drug to which resistant parasites were hypersensitive (the drug EC50  
 741 was 100-times lower in the resistant genotype than the sensitive one). The second phase ran  
 742 for 100 years, and once complete, the parasite population was fully susceptible. In the third  
 743 phase, we imported new infections at a rate low enough to ensure that the previously imported  
 744 mutation either established or went extinct before a new resistant mutation was imported  
 745 (Supplementary file 1: section 5.1). The third phase ran until one mutation established (over  
 746 50% of infected humans carried the resistant genotype).

747 The probability of establishment,  $P_e$ , can be estimated based on the average number of  
 748 mutations that are imported until one mutation establishes,  $N_e$ , as follows (the probability of a  
 749 successful event can be estimated as one divided by the mean number of independent trials  
 750 required to achieve the first success [109]),

$$751 \quad P_e = \frac{1}{N_e}.$$

752 We simulated 300 stochastic realisations,  $R$ , and estimated  $P_e$ , as,

$$753 \quad P_e = \frac{1}{N_e} = \frac{1}{(\sum_{j=1}^R N_{m,j})/R} = \frac{R}{\sum_{j=1}^R N_{m,j}},$$

754 where  $N_{m,j}$  is the number of imported mutations until one mutation established in run  $j$ . Re-  
 755 arranging the formula shows that  $P_e$  is equal to the number of mutations established in all  
 756 stochastic realisations (this number is equal to  $R$  as only one mutation established per  
 757 stochastic realisation) divided by the total number of mutations imported into all stochastic  
 758 realisations (mutations that became extinct and established). Note that in each stochastic  
 759 realisation, we estimated  $N_m$ , as,

$$760 \quad N_m = t_e N_i,$$

761 where  $t_e$  is defined as the last time that the number of infections with a resistant genotype was  
 762 equal to zero, i.e. the time (in years) until the arrival of the first mutation that successfully  
 763 establishes.  $N_i$  is the number of imported resistant infections per year. Note that OpenMalaria  
 764 specifies the number of imported infections,  $V$ , in numbers of imported infections per 1,000  
 765 people per year, and half of the imported mutations were sensitive. Thus, the number of  
 766 imported resistant infections that occurred until one established can be estimated as,



767

$$N_m = t_e \left( \frac{NV}{2(1000)} \right) = 5t_e V,$$

768 where  $N$  is the human population size. We set the population size to 10,000 to be  
769 computationally feasible (as since we were not measuring the selection coefficient, there was  
770 no need to minimise the influence of stochastic processes).

## 771 **Acknowledgements**

772 We sincerely acknowledge all members of the Disease Modelling Unit of the Swiss Tropical  
773 and Public Health Institute and Dr Raman Sharma from Liverpool School of Tropical Medicine  
774 for their inputs. Simulations were performed on the scientific computing core facility, sciCORE,  
775 at the University of Basel (<http://scicore.unibas.ch/>).

## 776 **Competing interests**

777 Authors declare no competing interests.

## 778 **Data and software availability**

779 We did not use individual participant-level data. Parameters values used in the model were  
780 informed from the literature as referred to in the main text or the supplementary file. The source  
781 code for OpenMalaria was developed using the C++ language and is available at  
782 <https://github.com/SwissTPH/openmalaria>. The analysis script was developed using the R  
783 software. All generated data and the code used for data analysis and visualization will be made  
784 available on request.

## 785 **Author contributions**

786 MAP Conceptualization. TM, MG, AJS, IMH, MAP Methodology; TM, MG, AJS Software; TM  
787 Validation; TM Formal analysis; TM, TL, IMH, and MAP Investigation; TM Data curation; TM,  
788 TL and MAP Writing – original draft preparation; TM, TL, MG, AJS, SLK, IMH, and MAP  
789 Writing – review & editing; TM Visualization; MAP Supervision; MAP Project administration;  
790 MAP Funding acquisition

## 791 **Corresponding author**

792 Name: Melissa Penny

793 Email: [melissa.penny@unibas.ch](mailto:melissa.penny@unibas.ch)

794 Institution: Swiss Tropical and Public Health Institute, Basel, Switzerland. University of Basel,  
795 Basel, Switzerland

## 796 **Funding**

797 This research was funded under the Swiss National Science Foundation Professorship of  
798 Melissa Penny (PP00P3\_170702).

## 799 References

- 800 1. WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva:  
801 World Health Organization; 2020. Available from:  
802 <https://www.who.int/publications/i/item/9789240015791>.
- 803 2. WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of  
804 surveillance (2010-2019). Geneva: World Health Organization; 2020. Available from:  
805 <https://www.who.int/publications/i/item/9789240012813>.
- 806 3. Farooq U, Mahajan R. Drug resistance in malaria. *Journal of Vector Borne Diseases*.  
807 2004;41(3/4):45-53.
- 808 4. White N. Antimalarial drug resistance and combination chemotherapy. *Philosophical  
809 Transactions of the Royal Society of London Series B: Biological Sciences*.  
810 1999;354(1384):739-49. <https://doi.org/10.1098/rstb.2019.0802>
- 811 5. White NJ. Antimalarial drug resistance. *The Journal of Clinical Investigation*.  
812 2004;113(8):1084-92. <https://doi.org/10.1172/JCI21682>
- 813 6. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-  
814 resistant malaria. *The Lancet Infectious Diseases*. 2002;2(4):209-18.  
815 [https://doi.org/10.1016/s1473-3099\(02\)00239-6](https://doi.org/10.1016/s1473-3099(02)00239-6).
- 816 7. Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, et al.  
817 Independent emergence of the *Plasmodium falciparum* Kelch propeller domain mutant  
818 allele C580Y in Guyana. *The Journal of Infectious Diseases*. 2016;213(9):1472-5.  
819 <https://doi.org/10.1093/infdis/jiv752>.
- 820 8. Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al.  
821 Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum*  
822 kelch13 R561H mutant parasites in Rwanda. *Nature Medicine*. 2020;26(10):1602-8.  
823 <https://doi.org/10.1038/s41591-020-1005-2>
- 824 9. Uwimana A, Umulisa N, Venkatesan M, Szigel SS, Zhou Z, Munyaneza T, et al.  
825 Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite  
826 clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.  
827 *The Lancet Infectious Diseases*. 2021;21:1120-8. [https://doi.org/10.1016/S1473-  
828 3099\(21\)00142-0](https://doi.org/10.1016/S1473-3099(21)00142-0)
- 829 10. Miotto O, Sekihara M, Tachibana S-I, Yamauchi M, Pearson RD, Amato R, et al.  
830 Emergence of artemisinin-resistant *Plasmodium falciparum* with kelch13 C580Y  
831 mutations on the island of New Guinea. *PLoS Pathogens*. 2020;16(12):e1009133.  
832 <https://doi.org/10.1371/journal.ppat.1009133>
- 833 11. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al.  
834 Evidence of artemisinin-resistant malaria in Africa. *New England Journal of Medicine*.  
835 2021;385(13):1163-71. <https://doi.org/10.1056/NEJMoa2101746>
- 836 12. Van der Pluijm RW, Tripura R, Høglund RM, Phyto AP, Lek D, Ul Islam A, et al. Triple  
837 artemisinin-based combination therapies versus artemisinin-based combination  
838 therapies for uncomplicated *Plasmodium falciparum* malaria: a multicentre, open-label,  
839 randomised clinical trial. *The Lancet*. 2020;395:1345-60. [https://doi.org/10.1016/S0140-  
840 6736\(20\)30552-3](https://doi.org/10.1016/S0140-6736(20)30552-3)
- 841 13. Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological  
842 principles of drug-resistance evolution in infectious diseases. *The Lancet Infectious  
843 Diseases*. 2011;11(3):236-47. [https://doi.org/10.1016/S1473-3099\(10\)70264-4](https://doi.org/10.1016/S1473-3099(10)70264-4)
- 844 14. Mackinnon M. Drug resistance models for malaria. *Acta Tropica*. 2005;94(3):207-17.  
845 <https://doi.org/10.1016/j.actatropica.2005.04.006>.

- 846 15. Hastings IM. The origins of antimalarial drug resistance. Trends in Parasitology.  
847 2004;20(11):512-8. <https://doi.org/10.1056/NEJMp1403340>.
- 848 16. Hastings IM, Hardy D, Kay K, Sharma R. Incorporating genetic selection into individual-  
849 based models of malaria and other infectious diseases. Evolutionary Applications.  
850 2020;13(10):2723-39. <https://doi.org/10.1111/eva.13077>
- 851 17. Hastings I, Mackinnon M. The emergence of drug-resistant malaria. Parasitology.  
852 1998;117(5):411-7. <https://doi.org/10.1017/s0031182098003291>
- 853 18. Klein EY. The impact of heterogeneous transmission on the establishment and spread  
854 of antimalarial drug resistance. Journal of Theoretical Biology. 2014;340:177-85.  
855 <https://doi.org/10.1016/j.jtbi.2013.09.022>
- 856 19. Antao T, Hastings IM. Environmental, pharmacological and genetic influences on the  
857 spread of drug-resistant malaria. Proceedings of the Royal Society B: Biological  
858 Sciences. 2011;278(1712):1705-12. <https://doi.org/10.1098/rspb.2010.1907>
- 859 20. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared  
860 principles across diverse targets and organisms. Nature Reviews Genetics.  
861 2015;16(8):459-71. <https://doi.org/10.1038/nrg3922>.
- 862 21. Huijben S, Bell AS, Sim DG, Tomasello D, Mideo N, Day T, et al. Aggressive  
863 chemotherapy and the selection of drug resistant pathogens. PLoS Pathogens.  
864 2013;9(9):e100357. <https://doi.org/10.1371/journal.ppat.1003578>
- 865 22. Miotto O, Amato R, Ashley EA, MaInnis B, Almagro-Garcia J, Amaratunga C, et al.  
866 Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. Nature Genetics.  
867 2015;47(3):226-34. <https://doi.org/10.1038/ng.3189>
- 868 23. Slater HC, Okell LC, Ghani AC. Mathematical modelling to guide drug development for  
869 malaria elimination. Trends in Parasitology. 2017;33(3):175-84.  
870 <https://doi.org/10.1016/j.pt.2016.09.004>.
- 871 24. Mackinnon M, Marsh K. The selection landscape of malaria parasites. Science.  
872 2010;328(5980):866-71. <https://doi.org/10.1126/science.1185410>
- 873 25. Bushman M, Antia R, Udhayakumar V, de Roode JC. Within-host competition can delay  
874 evolution of drug resistance in malaria. PLoS Biology. 2018;16(8):1-25.  
875 <https://doi.org/10.1371/journal.pbio.2005712>
- 876 26. Brock AR, Ross JV, Parikh S, Esterman A. The role of antimalarial quality in the  
877 emergence and transmission of resistance. Medical Hypotheses. 2018;111:49-54.  
878 <https://doi.org/10.1016/j.mehy.2017.12.018>
- 879 27. Watkins WM, Mosobo M. Treatment of *Plasmodium falciparum* malaria with  
880 pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long  
881 elimination half-life. Royal Society of Tropical Medicine and Hygiene. 1993;87(1):75-8.  
882 [https://doi.org/10.1016/0035-9203\(93\)90431-o](https://doi.org/10.1016/0035-9203(93)90431-o)
- 883 28. Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NPJ, White NJ. Spread  
884 of anti-malarial drug resistance: Mathematical model with implications for ACT drug  
885 policies. Malaria Journal. 2008;7(1):229. <https://doi.org/10.1186/1475-2875-7-229>
- 886 29. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al.  
887 Hyperparasitaemia and low dosing are an important source of anti-malarial drug  
888 resistance. Malaria Journal. 2009;8(1):253. <https://doi.org/10.1186/1475-2875-8-253>
- 889 30. Chiyaka C, Garira W, Dube S. Effects of treatment and drug resistance on the  
890 transmission dynamics of malaria in endemic areas. Theoretical Population Biology.  
891 2009;75(1):14-29. <https://doi.org/10.1016/j.tpb.2008.10.002>

- 892 31. Esteva L, Gumel AB, De León CV. Qualitative study of transmission dynamics of drug-  
893 resistant malaria. *Mathematical and Computer Modelling*. 2009;50(3-4):611-30.  
894 <https://doi.org/10.1016/j.mcm.2009.02.012>
- 895 32. Koella J, Antia R. Epidemiological models for the spread of anti-malarial resistance.  
896 *Malaria Journal*. 2003;2(1):3. <https://doi.org/10.1186/1475-2875-2-3>
- 897 33. Lee TE, Penny MA. Identifying key factors of the transmission dynamics of drug-resistant  
898 malaria. *Journal of Theoretical Biology*. 2019;462:210-20.  
899 <https://doi.org/10.1016/j.jtbi.2018.10.050>
- 900 34. Lee TE, Bonhoeffer S, Penny MA. The competition dynamics of drug resistant malaria.  
901 *BioRxiv*. 2021. <https://doi.org/10.1101/2021.01.25.427822>
- 902 35. Legros M, Bonhoeffer S. A combined within-host and between-hosts modelling  
903 framework for the evolution of resistance to antimalarial drugs. *Journal of the Royal*  
904 *Society Interface*. 2016;13(117):20160148. <https://doi.org/10.1098/rsif.2016.0148>
- 905 36. Tchuente JM, Chiyaka C, Chan D, Matthews A, Mayer G. A mathematical model for  
906 antimalarial drug resistance. *Mathematical Medicine Biology: A Journal of the IMA*.  
907 2011;28(4):335-55. <https://doi.org/10.1093/imammb/dqq017>
- 908 37. Tumwiine J, Mugisha J, Luboobi LS. A mathematical model for the dynamics of malaria  
909 in a human host and mosquito vector with temporary immunity. *Applied Mathematics and*  
910 *Computation*. 2007;189(2):1953-65. <https://doi.org/10.1016/j.amc.2006.12.084>
- 911 38. Macdonald G. *The Epidemiology and Control of Malaria*. London: Oxford University  
912 Press; 1957.
- 913 39. Ross R. Some a priori pathometric equations. *British Medical Journal*. 1915;1(2830):546-  
914 7. <https://doi.org/10.1136/bmj.1.2830.546>
- 915 40. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, et al. Altered  
916 temporal response of malaria parasites determines differential sensitivity to artemisinin.  
917 *Proceedings of the National Academy of Sciences*. 2013;110(13):5157-62.  
918 <https://doi.org/10.1073/pnas.1217452110>
- 919 41. Wang J, Xu C, Lun Z-R, Meshnick SR. Unpacking 'artemisinin resistance'. *Trends in*  
920 *Pharmacological Sciences*. 2017;38(6):506-11.  
921 <https://doi.org/10.1016/j.tips.2017.03.007>.
- 922 42. Sá JM, Kaslow SR, Krause MA, Melendez-Muniz VA, Salzman RE, Kite WA, et al.  
923 Artemisinin resistance phenotypes and K13 inheritance in a *Plasmodium falciparum*  
924 cross and *Aotus* model. *Proceedings of the National Academy of Sciences*.  
925 2018;115(49):12513-8. <https://doi.org/10.1073/pnas.1813386115>
- 926 43. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin  
927 susceptibility of *Plasmodium falciparum* ring stages in western Cambodia. *Antimicrobial*  
928 *Agents and Chemotherapy*. 2013;57(2):914-23. <https://doi.org/10.1128/AAC.01868-12>.
- 929 44. Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, et al. Distinctive origin of artemisinin-  
930 resistant *Plasmodium falciparum* on the China-Myanmar border. *Scientific Reports*.  
931 2016;6:20100. <https://doi.org/10.1038/srep20100>
- 932 45. Chaorattanakawee S, Lon C, Jongsakul K, Gawee J, Sok S, Sundrakes S, et al. Ex vivo  
933 piperazine resistance developed rapidly in *Plasmodium falciparum* isolates in northern  
934 Cambodia compared to Thailand. *Malaria Journal*. 2016;15(1):1-12.  
935 <https://doi.org/10.1186/s12936-016-1569-y>
- 936 46. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, et  
937 al. Ex vivo drug susceptibility testing and molecular profiling of clinical *Plasmodium*  
938 *falciparum* isolates from Cambodia from 2008 to 2013 suggest emerging piperazine  
939 resistance. *Antimicrobial Agents Chemotherapy*. 2015;59(8):4631-43.  
940 <https://doi.org/10.1128/AAC.00366-15>

- 941 47. Tahita MC, Tinto H, Yarga S, Kazienga A, Traore M, Valea I, et al. Ex vivo anti-malarial  
942 drug susceptibility of *Plasmodium falciparum* isolates from pregnant women in an area  
943 of highly seasonal transmission in Burkina Faso. *Malaria Journal*. 2015;14(1):1-6.  
944 <https://doi.org/10.1186/s12936-015-0769-1>
- 945 48. Watson OJ, Gao B, Nguyen TD, Tran TN-A, Penny MA, Smith DL, et al. Pre-existing  
946 partner-drug resistance facilitates the emergence and spread of artemisinin resistance:  
947 a consensus modelling study. *BioRxiv*. 2021. <https://doi.org/10.1101/2021.04.08.437876>
- 948 49. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of  
949 drug elimination half-life. *Philosophical Transactions of the Royal Society of London*  
950 *Series B: Biological Sciences*. 2002;357(1420):505-19.  
951 <https://doi.org/10.1098/rstb.2001.1036>
- 952 50. Molineaux L, Diebner H, Eichner M, Collins W, Jeffery G, Dietz K. *Plasmodium*  
953 *falciparum* parasitaemia described by a new mathematical model. *Parasitology*.  
954 2001;122(4):379 - 91. <https://doi.org/10.1017/S0031182001007533>
- 955 51. Bertrand J, Mentré F. Mathematical expressions of the pharmacokinetic and  
956 pharmacodynamic models implemented in the Monolix software. Paris Diderot  
957 University; 2008.
- 958 52. Kay K, Hastings IM. Improving pharmacokinetic-pharmacodynamic modeling to  
959 investigate anti-infective chemotherapy with application to the current generation of  
960 antimalarial drugs. *PLoS Computational Biology*. 2013;9(7):e1003151.  
961 <https://doi.org/10.1371/journal.pcbi.1003151>
- 962 53. Johnston GL, Gething PW, Hay SI, Smith DL, Fidock DA. Modeling within-host effects of  
963 drugs on *Plasmodium falciparum* transmission and prospects for malaria elimination.  
964 *PLoS Computational Biology*. 2014;10(1):e1003434.  
965 <https://doi.org/10.1371/journal.pcbi.1003434>
- 966 54. Winter K, Hastings IM. Development, evaluation, and application of an in silico model for  
967 antimalarial drug treatment and failure. *Antimicrobial Agents Chemotherapy*.  
968 2011;55(7):3380-92. <https://doi.org/10.1128/AAC.01712-10>
- 969 55. Grow A, Hilton J. Statistical emulation. Wiley Online Library. 2018:1-8.  
970 <https://doi.org/10.1002/9781118445112.stat07987>
- 971 56. WHO. WHO Guidelines for malaria. Geneva: World health organization; 2021. Available  
972 from: <https://www.who.int/publications/i/item/guidelines-for-malaria>.
- 973 57. Gramacy RB. tgp: an R package for Bayesian nonstationary, semiparametric nonlinear  
974 regression and design by treed Gaussian process models. *Journal of Statistical*  
975 *Software*; 2007
- 976 58. Kay K, Hastings IM. Measuring windows of selection for anti-malarial drug treatments.  
977 *Malaria Journal*. 2015;14(1):1-10. <https://doi.org/10.1186/s12936-015-0810-4>
- 978 59. Hastings IM, Hodel EM, Kay K. Quantifying the pharmacology of antimalarial drug  
979 combination therapy. *Scientific Reports*. 2016;6(1):32762.  
980 <https://doi.org/10.1038/srep32762>
- 981 60. Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, et al. Origins  
982 of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective  
983 genetic study. *Lancet Infectious Diseases*. 2018;18(3):337-45.  
984 [https://doi.org/10.1016/s1473-3099\(18\)30068-9](https://doi.org/10.1016/s1473-3099(18)30068-9)
- 985 61. Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, et  
986 al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic  
987 epidemiology study. *The Lancet Infectious Diseases*. 2019;19(9):943-51.  
988 [https://doi.org/10.1016/S1473-3099\(19\)30392-5](https://doi.org/10.1016/S1473-3099(19)30392-5)



- 989 62. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against  
990 falciparum malaria on the Cambodia-Thailand border. *Emerging Infectious Diseases*.  
991 2008;14(5):716-9. <https://doi.org/10.3201/eid1405.071601>
- 992 63. Ehrlich HY, Bei AK, Weinberger DM, Warren JL, Parikh S. Mapping partner drug  
993 resistance to guide antimalarial combination therapy policies in sub-Saharan Africa.  
994 *Proceedings of the National Academy of Sciences*. 2021;118(29):e2100685118.  
995 <https://doi.org/10.1073/pnas.2100685118>
- 996 64. Edwards HM, Chinh VD, Le Duy B, Thanh PV, Thang ND, Trang DM, et al.  
997 Characterising residual malaria transmission in forested areas with low coverage of core  
998 vector control in central Viet Nam. *Parasites & vectors*. 2019;12(1):1-16.  
999 <https://doi.org/10.1186/s13071-019-3695-1>
- 1000 65. Chaumeau V, Fustec B, Hsel SN, Montazeau C, Nyo SN, Metaane S, et al.  
1001 Entomological determinants of malaria transmission in Kayin state, Eastern Myanmar: a  
1002 24-month longitudinal study in four villages. *Wellcome Open Research*. 2018;3.  
1003 <https://doi.org/10.12688/wellcomeopenres.14761.4>
- 1004 66. Edwards HM, Sriwichai P, Kirabittir K, Prachumsri J, Chavez IF, Hii J. Transmission risk  
1005 beyond the village: entomological and human factors contributing to residual malaria  
1006 transmission in an area approaching malaria elimination on the Thailand–Myanmar  
1007 border. *Malaria journal*. 2019;18(1):1-20. <https://doi.org/10.1186/s12936-019-2852-5>
- 1008 67. Hay SI, Rogers DJ, Toomer JF, Snow RW. Annual *Plasmodium falciparum*  
1009 entomological inoculation rates (EIR) across Africa: literature survey, Internet access and  
1010 review. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.  
1011 2000;94(2):113-27. [https://doi.org/10.1016/S0035-9203\(00\)90246-3](https://doi.org/10.1016/S0035-9203(00)90246-3)
- 1012 68. Yamba EI, Tompkins AM, Fink AH, Ermert V, Amelie MD, Amekudzi LK, et al. Monthly  
1013 Entomological Inoculation Rate Data for Studying the Seasonality of Malaria  
1014 Transmission in Africa. *Data*. 2020;5(2):31. <https://doi.org/10.3390/data5020031>
- 1015 69. Hastings IM. A model for the origins and spread of drug-resistant malaria. *Parasitology*.  
1016 1997;115 ( Pt 2):133-41. <https://doi.org/10.1017/s0031182097001261>
- 1017 70. Siddiqui MR, Willis A, Bil K, Singh J, Sompwe EM, Ariti C. Adherence to artemisinin  
1018 combination therapy for the treatment of uncomplicated malaria in the Democratic  
1019 Republic of the Congo. *F1000Research*. 2015;4:4:51.  
1020 <https://doi.org/10.12688/f1000research.6122.2>.
- 1021 71. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria  
1022 treatment: a systematic review of the literature on adherence to antimalarial drugs. *PloS*  
1023 *One*. 2014;9(1):e84555. <https://doi.org/10.1371/journal.pone.0084555>
- 1024 72. Krishna S. Triple artemisinin-containing combination anti-malarial treatments should be  
1025 implemented now to delay the emergence of resistance: the case against. *Malaria*  
1026 *Journal*. 2019;18(1):339. <https://doi.org/10.1186/s12936-019-2976-7>
- 1027 73. Hastings IM, Hodel EM. Pharmacological considerations in the design of anti-malarial  
1028 drug combination therapies—is matching half-lives enough? *Malaria Journal*.  
1029 2014;13(1):1-15. <https://doi.org/10.1186/1475-2875-13-62>
- 1030 74. Kay K, Hodel EM, Hastings IM. Altering antimalarial drug regimens may dramatically  
1031 enhance and restore drug effectiveness. *Antimicrobial Agents Chemotherapy*.  
1032 2015;59(10):6419-27. <https://doi.org/10.1128/AAC.00482-15>
- 1033 75. Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, et al. Targeting the cell  
1034 stress response of *Plasmodium falciparum* to overcome artemisinin resistance. *PLoS*  
1035 *Biology*. 2015;13(4):e1002132. <https://doi.org/10.1371/journal.pbio.1002132>

- 1036 76. Khoury DS, Cao P, Zaloumis SG, Davenport MP, Consortium IAAtM. Artemisinin  
1037 Resistance and the Unique Selection Pressure of a Short-acting Antimalarial. Trends in  
1038 Parasitology. 2020;36(11):884-7. <https://doi.org/10.1016/j.pt.2020.07.004>
- 1039 77. Crow JF, Motoo K. An introduction to population genetics theory. Jodhpur: Scientific  
1040 Publishers; 2017.
- 1041 78. Hodel EM, Kay K, Hastings IM. Incorporating stage-specific drug action into  
1042 pharmacological modeling of antimalarial drug treatment. Antimicrobial Agents and  
1043 Chemotherapy. 2016;60(5):2747-56. <https://doi.org/10.1128/AAC.01172-15>
- 1044 79. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of  
1045 artemisinin resistance in *Plasmodium falciparum* malaria. New England Journal of  
1046 Medicine. 2014;371(5):411-23. <https://doi.org/10.1056/NEJMoa1314981>
- 1047 80. Witmer K, Dahalan FA, Delves MJ, Yahiya S, Watson OJ, Straschil U, et al. Transmission  
1048 of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug  
1049 pressure. Antimicrobial Agents and Chemotherapy. 2020;65(1):e00898-20.  
1050 <https://doi.org/10.1128/AAC.00898-20>.
- 1051 81. Dye C, Williams BG. Multigenic drug resistance among inbred malaria parasites.  
1052 Proceedings of the Royal Society of London Series B: Biological Sciences.  
1053 1997;264(1378):61-7. <https://doi.org/10.1098/rspb.1997.0009>
- 1054 82. Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, et al. Origin  
1055 and evolution of sulfadoxine resistant *Plasmodium falciparum*. PLoS Pathogens.  
1056 2010;6(3):e1000830. <https://doi.org/10.1371/journal.ppat.1000830>
- 1057 83. Chitnis N, Hardy D, Smith T. A periodically-forced mathematical model for the seasonal  
1058 dynamics of malaria in mosquitoes. Bulletin of Mathematical Biology. 2012;74(5):1098-  
1059 124. <https://doi.org/10.1007/s11538-011-9710-0>
- 1060 84. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, et al. Mathematical  
1061 modeling of the impact of malaria vaccines on the clinical epidemiology and natural  
1062 history of *Plasmodium falciparum* malaria: Overview. The American Journal of Tropical  
1063 Medicine and Hygiene. 2006;75(2\_suppl):1-10.  
1064 [https://doi.org/10.4269/ajtmh.2006.75.2\\_suppl.0750001](https://doi.org/10.4269/ajtmh.2006.75.2_suppl.0750001)
- 1065 85. Smith T, Maire N, Ross A, Penny M, Chitnis N, Schapira A, et al. Towards a  
1066 comprehensive simulation model of malaria epidemiology and control. Parasitology.  
1067 2008;135(13):1507-16. <https://doi.org/10.1017/S0031182008000371>
- 1068 86. Reiker T, Golumbeanu M, Shattock A, Burgert L, Smith TA, Filippi S, et al. Emulator-  
1069 based Bayesian optimization for efficient multi-objective calibration of an individual-  
1070 based model of malaria. Nature Communications 2021;12(1):1-11.  
1071 <https://doi.org/10.1038/s41467-021-27486-z>
- 1072 87. Smith T, Ross A, Maire N, Rogier C, Trape J-F, Molineaux L. An epidemiologic model of  
1073 the incidence of acute illness in *Plasmodium falciparum* malaria. The American Journal  
1074 of Tropical Medicine and Hygiene. 2006;75(2\_suppl):56-62.  
1075 <https://doi.org/10.4269/ajtmh.2006.75.56>
- 1076 88. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic model of severe morbidity and  
1077 mortality caused by *Plasmodium falciparum*. The American Journal of Tropical Medicine  
1078 and Hygiene. 2006;75(2\_suppl):63-73. <https://doi.org/10.4269/ajtmh.2006.75.63>
- 1079 89. Ross A, Smith T. The effect of malaria transmission intensity on neonatal mortality in  
1080 endemic areas. The American Journal of Tropical Medicine and Hygiene  
1081 2006;75:74-81. <https://doi.org/10.4269/ajtmh.2006.75.74>.
- 1082 90. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural  
1083 immunity to asexual blood stages of *Plasmodium falciparum* malaria in endemic areas.

- 1084 The American Journal of Tropical Medicine and Hygiene. 2006;75:19-31.  
1085 <https://doi.org/10.4269/ajtmh.2006.75.19>
- 1086 91. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, et al. An approach to model  
1087 the costs and effects of case management of *Plasmodium falciparum* malaria in sub-  
1088 Saharan Africa. The American Journal of Tropical Medicine and Hygiene.  
1089 2006;75(2\_suppl):90-103. <https://doi.org/10.4269/ajtmh.2006.75.90>.
- 1090 92. Ross A, Killeen G, Smith T. Relationships between host infectivity to mosquitoes and  
1091 asexual parasite density in *Plasmodium falciparum*. The American Journal of Tropical  
1092 Medicine and Hygiene. 2006;75(2\_suppl):32-7.  
1093 <https://doi.org/10.4269/ajtmh.2006.75.32>
- 1094 93. Charles B, Blomgren A, Nasveld P, Kitchener S, Jensen A, Gregory R, et al. Population  
1095 pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria  
1096 infection during field deployment. European Journal of Clinical Pharmacology.  
1097 2007;63(3):271-8. <https://doi.org/10.1007/s00228-006-0247-3>
- 1098 94. Hodel EMS, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywany AM, et al. Population  
1099 pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in  
1100 Cambodian and Tanzanian malaria patients. Malaria Journal. 2013;12(1):235.  
1101 <https://doi.org/10.1186/1475-2875-12-235>.
- 1102 95. Jullien V, Valecha N, Srivastava B, Sharma B, Kiechel J-R. Population pharmacokinetics  
1103 of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in  
1104 Indian patients for the treatment of acute uncomplicated *Plasmodium falciparum* malaria.  
1105 Malaria Journal. 2014;13(1):187. <https://doi.org/10.1186/1475-2875-13-187>
- 1106 96. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, et al.  
1107 Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children  
1108 with uncomplicated malaria. Antimicrobial Agents and Chemotherapy. 2008;52(1):237-  
1109 43. <https://doi.org/10.1128/AAC.00555-07>.
- 1110 97. Maganda BA, Ngaimisi E, Kamuhabwa AA, Akillu E, Minzi OM. The influence of  
1111 nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of  
1112 lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.  
1113 Malaria Journal. 2015;14(1):179. <https://doi.org/10.1186/s12936-015-0695-2>
- 1114 98. Das JL, Dondorp AM, Nosten F, Phyo AP, Hanpithakpong W, Ringwald P, et al.  
1115 Population pharmacokinetic and pharmacodynamic modeling of artemisinin resistance  
1116 in Southeast Asia. The AAPS Journal. 2017;19(6):1842-54.  
1117 <https://doi.org/10.1208/s12248-017-0141-1>
- 1118 99. Das JPL, Kyaw MP, Nyunt MH, Chit K, Aye KH, Aye MM, et al. Population  
1119 pharmacokinetic and pharmacodynamic properties of artesunate in patients with  
1120 artemisinin sensitive and resistant infections in Southern Myanmar. Malaria Journal.  
1121 2018;17(1):126. <https://doi.org/10.1186/s12936-018-2278-5>
- 1122 100. Binois M, Gramacy R. hetGP: Heteroskedastic Gaussian process modeling and  
1123 sequential design in R. Journal of Statistical Software. 2021;98. (1):1-44.  
1124 <https://doi.org/10.18637/jss.v098.i13>
- 1125 101. Golumbeanu M, Yang G, Camponovo F, Stuckey EM, Hamon N, Mondy M, et al.  
1126 Combining machine learning and mathematical models of disease dynamics to guide  
1127 development of novel disease interventions. MedRxiv. 2021:2021.01.05.21249283.  
1128 <https://doi.org/10.1101/2021.01.05.21249283>
- 1129 102. Kublin JG, Cortese JF, Njunju EM, G. Mukadam RA, Wirima JJ, Kazembe PN, et al.  
1130 Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation  
1131 of chloroquine use in Malawi. The Journal of Infectious Diseases. 2003;187(12):1870-5.  
1132 <https://doi.org/10.1086/375419>



- 1133 103. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, et al. Recovery of chloroquine  
 1134 sensitivity and low prevalence of the *Plasmodium falciparum* chloroquine resistance  
 1135 transporter gene mutation K76T following the discontinuance of chloroquine use in  
 1136 Malawi. The American Journal of Tropical Medicine and Hygiene. 2003;68(4):413-5.  
 1137 <https://doi.org/10.4269/ajtmh.2003.68.413>
- 1138 104. Kilian AH, Metzger WG, Mutschelknauss EJ, Kabagambe G, Langi P, Korte R, et al.  
 1139 Reliability of malaria microscopy in epidemiological studies: results of quality control.  
 1140 Tropical Medicine and International Health. 2000;5(1):3-8.  
 1141 <https://doi.org/10.1046/j.1365-3156.2000.00509.x>
- 1142 105. Murray CK, Gasser RA, Jr., Magill AJ, Miller RS. Update on rapid diagnostic testing for  
 1143 malaria. Clinical Microbiology Reviews. 2008;21(1):97-110.  
 1144 <https://doi.org/10.1128/cmr.00035-07>
- 1145 106. Ekström AM, Clark J, Byass P, Lopez A, De Savigny D, Moyer CA, et al. INDEPTH  
 1146 network: contributing to the data revolution. The Lancet Diabetes & Endocrinology.  
 1147 2016;4(2):97. [https://doi.org/10.1016/S2213-8587\(15\)00495-7](https://doi.org/10.1016/S2213-8587(15)00495-7)
- 1148 107. Sobol IM. Global sensitivity indices for nonlinear mathematical models and their Monte  
 1149 Carlo estimates. Mathematics and Computers in Simulation. 2001;55(1-3):271-80.  
 1150 [https://doi.org/10.1016/S0378-4754\(00\)00270-6](https://doi.org/10.1016/S0378-4754(00)00270-6)
- 1151 108. Bertrand Iooss SDV, Alexandre Janon and Gilles Pujol, with contributions from Baptiste  
 1152 Broto, Khalid Boumhaout, Thibault Delage, Reda El Amri, Jana Fruth, Laurent Gilquin,  
 1153 Joseph Guillaume, Marouane Idrissi, Loic Le Gratiet, Paul Lemaitre, Aman-dine Marrel,  
 1154 Anouar Meynaoui, Barry L. Nelson, Filippo Monari, Roelof Oomen, Oldrich Rakovec,  
 1155 Bernardo Ramos, Olivier Roustant, Eun-hye Song, Jeremy Staum, Roman Sueur, Taieb  
 1156 Touati, Frank Weber. Global Sensitivity Analysis of Model Outputs. 1.26.1 ed2021  
 1157 Available from: <https://cran.r-project.org/web/packages/sensitivity/sensitivity.pdf>
- 1158 109. Dekking FM, Kraaikamp C, Lopuhaä HP, Meester LE. A Modern Introduction to  
 1159 Probability and Statistics: Understanding why and how: Springer Science & Business  
 1160 Media; 2005.

1 **The influence of biological, epidemiological, and treatment**  
2 **factors on the establishment and spread of drug-resistant**  
3 ***Plasmodium falciparum***

4 **Supplementary file**

5 Thierry Masserey<sup>1, 2</sup>, Tamsin Lee<sup>1, 2</sup>, Monica Golumbeanu<sup>1, 2</sup>, Andrew J Shattock<sup>1, 2</sup>, Sherrie L Kelly<sup>1, 2</sup>,  
6 Ian M Hastings<sup>3</sup>, Melissa A Penny<sup>1, 2\*</sup>

7 <sup>1</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

8 <sup>2</sup> University of Basel, Basel, Switzerland

9 <sup>3</sup> Liverpool School of Tropical Medicine, Liverpool, UK

10 \*corresponding author: melissa.penny@unibas.ch


11 **1. Supplementary results**

12 **1.1 Supplementary figures that illustrate the results**

13 **Figure S1**

14 **Influence of the access to treatment and degree of resistance on the selection coefficients of a**  
15 **genotype resistant to drug A or drug B used in monotherapy.**

16 Lines represent medians and shaded areas represent interquartile ranges of the selection coefficients  
17 estimated during the global sensitivity analysis over the parameter range for levels of access to  
18 treatment (10% to 80%), the degree of resistance to drug A (1- to 50-fold decrease in E<sub>max</sub>), and the  
19 degree of resistance to drug B (1- and 20-fold increase in EC<sub>50</sub>).




20 **Figure S2**

21 **Magnitude and direction of effect of drug properties and fitness cost on predicted selection**  
 22 **coefficients for low and high levels of transmission, degree of drug resistance, treatment**  
 23 **adherence, in seasonal or perennial settings with monotherapy or combination treatment.**

24 The solid and dashed lines represent the median selection coefficients over the parameter ranges  
 25 estimated in each setting that had low access to treatment (10%) and an *entomological inoculation rate*  
 26 (EIR) of 5 (solid lines) or 500 (dashed lines) inoculations per person per year. Settings varied in their  
 27 seasonality pattern and level of adherence to treatment (*low=67% and high=100%*). For each treatment  
 28 profile, we show results for parasites with two different degrees of resistance; degree of resistance of 7  
 29 (low) and 18 (high) to drug A (Emax shift), 2.5 (low) and 10 (high) to drug B (EC50 shift), and with  
 30 combination of drugs A and B, 7 (low) and 18 (high) to drug A and 10 to drug B. The parameter ranges  
 31 were the following: fitness cost (1, 1.1); drug A half-life (0.035, 0.175) days; drug B half-life (6, 22) days;  
 32 Cmax/EC50 ratio of drug A (55, 312); Cmax/EC50 ratio of drug B at a high level of adherence to  
 33 treatment (5.4, 21.7); and at a low level of adherence (4.0, 16.2).


Factors: Fitness cost Half-life drug A (days) Half-life drug B (days) Cmax/EC50 drug A Cmax/EC50 drug B



34 **Figure S3**

35 **First-order indices describing level of importance of each factor from the constrained sensitivity**  
 36 **analysis of the spread of a genotype resistant to drug A used in monotherapy.**


37 The first-order indices were assessed for parasites that had different degrees of resistance to drug A  
 38 (low=7 and high=18 fold decrease in Emax) in settings that differ in their levels of access to treatment  
 39 (high=10% and low=80%), levels of transmission (5, 10, and 500 inoculations per person per year),  
 40 transmission patterns (no seasonality and seasonality), and levels of adherence to treatment (low=67%,  
 41 and high=100%). The explored parameter ranges were the following: the fitness cost (1, 1.1); the half-  
 42 life of drug A (0.035, 0.175) days; the ratio Cmax/EC50 for drug A (55, 312); the Emax of drug A (27.5,  
 43 31.0) per day; and the diagnostic detection limit (2, 50) parasites/microliter.



44 **Figure S4**

45 **First-order indices of each factor from the constrained sensitivity analysis of the spread of a**  
 46 **genotype resistant to drug B used in monotherapy.**


47 The first-order indices were assessed for parasites that had different degrees of resistance to drug B  
 48 (low=2.5 and high=10 fold increase in EC50) in settings that differ in their levels of access to treatment  
 49 (low=10 %, and high=80%), levels of transmission (5, 10, and 500 inoculations per person per year),  
 50 transmission patterns (no seasonality and seasonality), and levels of adherence to treatment (low=67%,  
 51 and high=100%). The explored parameter ranges were the following: the fitness cost (1, 1.1); the half-  
 52 life of drug B (6, 22) days; the ratio Cmax/EC50 for drug B at a high level of adherence to treatment (5.4,  
 53 21.7) and at a low level of adherence to treatment (4.0, 16.2); the Emax of drug B (3.45, 5.00) per day;  
 54 and the diagnostic detection limit (2, 50) parasites/microliter.



55 **Figure S5**

56 **First-order indices of each factor from the constrained sensitivity analysis of the spread of a**  
 57 **genotype resistant to drug A when drug A and drug B are used in combination.**


58 The first-order indices were assessed for parasites that had different degrees of resistance to drug A  
 59 (low=7 and high=18 fold decrease in Emax) in settings that differ in their levels of access to treatment  
 60 (low=10 %, and high=80%), levels of transmission (5, 10, and 500 inoculations per person per year),  
 61 transmission patterns (no seasonality and seasonality), and levels of adherence to treatment (low=67%,  
 62 and high=100%). The explored parameter ranges were the following: the fitness cost (1, 1.1); the half-  
 63 life of drug A (0.035, 0.175) days; the half-life of drug B (6, 22) days; the ratio Cmax/EC50 for drug A  
 64 (55, 312); the ratio Cmax/EC50 for drug B at a high level of adherence to treatment (5.4, 21.7) and at a  
 65 low level of adherence to treatment (4.0, 16.2); the Emax of drug A (27.5, 31.0) per day; the Emax of  
 66 drug B (3.45, 5) per day; and the diagnostic detection limit (2, 50) parasites/microliter.



67 **Figure S6**

68 **Distribution of selection coefficient across settings with high access to treatment.**

69 The selection coefficients were estimated for each treatment profile during the constrained sensitivity  
70 analysis of the spread of a resistant genotype having a low degree of resistance (equal to 7 for drug A  
71 (Emax shift), and to 2.5 for drug B (EC50 shift)), in settings with a high access to treatment (80%). The  
72 distributions are stratified by **(A)** the intensity of transmission **(B)** the seasonality pattern, and **(C)** the  
73 level of adherence to treatment in the settings.






74 **Figure S7**

75 **Treatment usage.**


76 The figure highlights the relationship between the transmission intensity (EIR) and the percentage of  
77 people that received treatment during a month (orange dots) and the percentage of infected people that  
78 received treatment during a month (blue dots). In this illustration, the level of access to treatment was  
79 equal to 80%, and the transmission was perennial.



80 **Figure S8**

81 **Distribution of selection coefficient across settings with a low access to treatment.**

82 The selection coefficients were estimated for each treatment profile during the constrained sensitivity  
83 analysis of the spread of a resistant genotype having a low degree of resistance (equal to 7 for drug A  
84 (Emax shift) and to 2.5 for drug B (EC50 shift)), in settings with a low access to treatment (10%). The  
85 distributions are stratified by (A) the intensity of transmission, (B) the seasonality pattern, and (C) the  
86 level of adherence to treatment in the settings.



## 1.2 The benefit of combination therapy

We illustrated the benefit of combination therapy by assessing how the degree of resistance to drug B influenced (i) the time taken for mutations conferring different degrees of resistance to drug A to spread from 1% to 25% of inoculations carrying the resistant genotype,  $T_{25}$ , (Figure 5, first y-axis) and (ii) their probability of establishment (Figure 5, second y-axis). Both the  $T_{25}$  and the probabilities of establishment were estimated based on selection coefficients predicted using the fitted emulators. To illustrate the impact of the transmission intensity on the two measurements, we predicted their values in low and high transmission levels. Note that, as discussed in the Results section, the relation between the selection coefficient and the probability of establishment changes slightly with the transmission level (Figure 4 of main text). In our example, drug A had the drug profile of dihydroartemisinin and drug B of piperazine. We set the level of access to treatment to 100%, assumed no fitness cost, the transmission was perennial, and the population adhered to treatment fully.


In a low transmission setting, in a parasite population fully susceptible to drug B, parasites resistant to drug A had a low probability of establishment and required many years to spread from 1% to 25% of inoculations carrying the resistant genotype. For example, a mutation with a low (3.5-fold decrease in  $E_{max}$ ) or high (13.5-fold decrease in  $E_{max}$ ) degree of resistance to drug A had a probability of 1/1000 or 1/100, respectively, to establish in the population and required more than 39 years or over 18 years, respectively, to spread from 1% to 25% of inoculations carrying the resistant genotype (Figure 5). The probability of establishment and  $T_{25}$  decreased tremendously with increased degrees of resistance of both genotypes to drug B (Figure 5). When the parasite population had a high degree of resistance to drug B (degree of resistance of 13.5), the probability of establishment increased to more than 1/10 and the  $T_{25}$  was reduced to approximately three years, independent of the degree of resistance to drug A (Figure 5). These results confirm that resistance to partner drugs facilitates the establishment and spread of partial artemisinin resistance.

In high transmission settings, higher degrees of resistance to drug B also accelerated the establishment and spread of parasites resistant to drug A (Figure 5). However, the probability of establishment and the rate of spread were consistently lower in high transmission settings compared with low transmission settings (Figure 5). In addition, for a specific  $T_{50}$ , the probability of establishment was slightly lower than in the low transmission setting due to the slight change in the relation between selection coefficients and probabilities of establishment with the EIR (see Results). These results agree with our observations that higher levels of within-host competition and immunity minimise the establishment and spread of resistance to artemisinin in high transmission settings.

**Figure S9**

**Illustration of the benefit of combination therapy on the evolution of drug resistance as time to 25% relative frequency of resistant genotypes.**

We estimated the probability of establishment and the time needed for parasites resistant to drug A to spread from 1% to 25% of inoculations carrying the resistant genotype,  $T_{25}$ , for multiple degrees of resistance of the resistant genotype to drug A ( $E_{max}$  shift) and multiple degrees of resistance of both genotypes to drug B ( $EC_{50}$  shift). We assumed Drug A has a similar drug profile of dihydroartemisinin and drug B of piperazine. We assumed a level of access to treatment of 100%. The population fully adhered to treatment. The resistant parasites had no fitness cost. The transmission intensity was equal to 5 (low transmission intensity) or 500 (high transmission intensity) inoculations per person per year (reflected low to very high transmission). The transmission was perennial.



## 2. Details on the parameterisation of OpenMalaria

Table S1

Pharmacokinetics (PK) and pharmacodynamics (PD) parameter values for drug A that were kept constant throughout the sensitivity analyses.

Component	Parameter	Value	Reference
PK	Volume distribution (l/kg)	1.49	[1]
	Treatment dosage (mg/kg)	4.00	[1, 2]
PD	Slope of the effect curve	4.00	[1, 2]

**Table S2**


**Pharmacokinetics (PK) and pharmacodynamics (PD) parameter values for drug B that were kept constant throughout the sensitivity analyses.**

<b>Component</b>	<b>Parameter</b>	<b>Value</b>	<b>Reference</b>
<b>PK</b>	Absorption rate (per day)	11.16	[3]
	Rate at which the drugs move from the central compartment to the peripheral compartment (per day)	8.46	[3]
	Rate at which the drugs move from the peripheral compartment to the central compartment (per day)	3.30	[3]
	Volume distribution (l/kg)	173.00	[3]
<b>PD</b>	Slope of the effect curve	6.00	[2, 3]

### Figure S10

#### The seasonal transmission of malaria.

Example of the EIR (inoculations per person per year) across a year in the seasonal setting of malaria transmission, based on field studies conducted in Tanzania. Here the total EIR is 360 inoculations per person per year.






### 3. Estimation of the selection coefficient

Figure S11

**Proof that the selection coefficient is not frequency-dependent in OpenMalaria.**


The figure illustrates the logit of the relative frequency of the resistant genotype over time when the initial relative frequency of infected humans carrying the resistant genotype was 5%. The selection coefficient (slope of the logistic regression) was less stable after six years because the percentage of inoculations carrying the sensitive genotype was lower than 0.5%. Thus, the influence of stochastic processes was strong.



**Figure S12**

**Illustration of typical simulations run in OpenMalaria to estimate the rate of spread of a drug-resistant genotype.**


The brown line represents the relative frequency of the resistant genotypes in inoculations. The solid line illustrates a simulation in which the resistant genotype spreads in the population (selection coefficient above 0). The dotted line illustrates a simulation in which the resistant genotype did not spread in the population (selection coefficient below 0). Phase 1 represents the burn-in phase. The vertical dotted black line highlights when we introduced the fitness cost and the drug for which the resistant genotype had reduced sensitivity. Phase 2 is the phase during which the rate of spread of the resistant genotype was assessed.



**Figure S13**

**Illustration of the estimation of the selection coefficient in seasonal settings.**

The black dots represent the logit of the relative frequency of the resistant genotype. The blue dots represent the logit of the moving average of relative frequency of the resistant genotype. The moving average of a measurement at a time  $t$  included all the measurements from six months before time  $t$  and six months after the time  $t$ . Using this method, the selection coefficient (slope of the logistic regression) was constant over time.




## 4. Fit of the emulators

Figure S14

### Accuracy of the emulators used for the global sensitivity analyses of each treatment profile.

For each treatment profile, the comparison between the selection coefficients of the test dataset estimated using OpenMalaria (i.e., the observed 'true' selection coefficient) and the corresponding prediction from the emulator during the final round of adaptive sampling. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.



**Figure S15**

**Accuracy of the emulators used for each constrained sensitivity analysis of the spread of a genotype resistant to drug A used in monotherapy in each setting with low access to treatment (10%).**

The comparison between the selection coefficients for the test dataset between the observed 'truth' from OpenMalaria, and the prediction from the emulators during the final round of adaptive sampling. The EIR is in inoculations per person per year (5, 10, and 500). The degree of resistance is the relative decrease in the Emax of the resistant genotype compared with the sensitive one. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.







Figure S17

Accuracy of the emulators used for each constrained sensitivity analysis of the spread of a genotype resistant to drug B used in monotherapy in each setting with low access to treatment (10%).

The comparison between the selection coefficients for the test dataset between the observed 'truth' from OpenMalaria, and the prediction from the emulators during the final round of adaptive sampling. The EIR is in inoculations per person per year (5, 10, or 500). The degree of resistance is the relative increase in the EC50 of the resistant genotype compared with the sensitive one. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.



**Figure S18**

**Accuracy of the emulators used for each constrained sensitivity analysis of the spread of a genotype resistant to drug B used in monotherapy in each setting with high access to treatment (80%).**

The comparison between the selection coefficients for the test dataset between the observed 'truth' from OpenMalaria, and the prediction from the emulators during the final round of adaptive sampling. The EIR is in inoculations per person per year (5, 10, or 500). The degree of resistance is the relative increase in the EC50 of the resistant genotype compared with the sensitive one. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.






Figure S19

Accuracy of the emulators used for each constrained sensitivity analysis of the spread of a genotype resistant to drug A, when used in combination with drug B, in each setting with low access to treatment (10%).

The comparison between the selection coefficients for the test dataset between the observed 'truth' from OpenMalaria, and the prediction from the emulators during the final round of adaptive sampling. The EIR is in inoculations per person per year (5, 10, or 500). The degree of resistance to drug A is the relative decrease in the Emax of the resistant genotype compared with the sensitive one. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.





Figure S20

Accuracy of the emulators used for each constrained sensitivity analysis of the spread of a genotype resistant to drug A, when used in combination with drug B, in each setting with high access to treatment (80%).

The comparison between the selection coefficients for the test dataset between the observed 'truth' from OpenMalaria, and the prediction from the emulators during the final round of adaptive sampling. The EIR is in inoculations per person per year (5, 10, or 500). The degree of resistance to drug A is the relative decrease in the Emax of the resistant genotype compared with the sensitive one. 'Cor' is the Spearman correlation coefficient, 'RMSE' is the root means squared error, and the blue lines are the linear regression fits.




## 5. Probability of establishment

Figure S21

Illustration of typical simulations run in OpenMalaria to estimate the probability of establishment of a drug-resistant genotype.

The brown curve represents the relative frequency of the resistant genotypes in inoculations. Phase 1 represents the burn-in phase. In the second phase, we introduced a drug to which resistant parasites were hypersensitive. In the last phase, we imported mutation conferring drug resistance at a low rate until one mutation established.



## 5.1 Calculation of the importation rate for each setting

The importation rate,  $I$ , (imported infections per 1,000 individuals per year), was calculated to mimic a mutation rate of  $5 \times 10^{-5}$  mutations per infection per year in each setting as in [4]. This low mutation rate ensured that the newly emerged genotype either established or became extinct before a new mutation was imported. The importation rate was calculated as:

$$I = \frac{1}{N} 2000 N_i u g,$$

where  $N$  is the human population size,  $N_i$  is the number of infections (i.e., the number of infected people),  $u$  is the mutation rate per infection (i.e., per transmission), and  $g$  is the number of malaria generations per year. Thus,  $N_i u g$  represents the number of *de novo* resistant mutations transmitted per year. This number was divided by the human population size and multiplied by 1,000 to obtain the number of imported infections per 1,000 persons per year. This is multiplied by two, as half of the imported infections were sensitive.

## 6. References

1. Kay K, Hastings IM. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. *PLoS Computational Biology*. 2013;9(7):e1003151. <https://doi.org/10.1371/journal.pcbi.1003151>.
2. Winter K, Hastings IM. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. *Antimicrobial Agents Chemotherapy*. 2011;55(7):3380-92. <https://doi.org/10.1128/AAC.01712-10>.
3. Hodel EMS, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywany AM, et al. Population pharmacokinetics of mefloquine, piperazine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. *Malaria Journal*. 2013;12(1):235. <https://doi.org/10.1186/1475-2875-12-235>.
4. Hastings IM, Hardy D, Kay K, Sharma R. Incorporating genetic selection into individual-based models of malaria and other infectious diseases. *Evolutionary Applications*. 2020;13(10):2723-39. <https://doi.org/10.1111/eva.13077>